

HB0389S01 compared with HB0389

{Omitted text} shows text that was in HB0389 but was omitted in HB0389S01

inserted text shows text that was not in HB0389 but was inserted into HB0389S01

DISCLAIMER: This document is provided to assist you in your comparison of the two bills. Sometimes this automated comparison will NOT be completely accurate. Therefore, you need to read the actual bills. This automatically generated document could contain inaccuracies caused by: limitations of the compare program; bad input data; or other causes.

1

Medical Cannabis Amendments

2026 GENERAL SESSION

STATE OF UTAH

Chief Sponsor: Jennifer Dailey-Provost

Senate Sponsor:

2

LONG TITLE

3

General Description:

4

This bill amends provisions related to medical cannabis.

5

Highlighted Provisions:

6

This bill:

7

▶ exempts medical cannabis processors from obtaining an additional license to process cannabinoid (hemp) products;

8

▶ creates a fee on medical cannabis purchases for use in enforcement of various laws;

9

▶ renames the Cannabis Production Establishment and Pharmacy Licensing Advisory Board to the Specialized Product Authority Licensing Board (licensing board);

10

▶ reconstitutes the licensing board's membership;

11

▶ amends provisions related to labeling and packaging;

12

▶ modifies the licensing board's duties;

13

▶ moves control of the Qualified Patient Enterprise Fund to the Department of Agriculture and Food(UDAF);

14

▶

HB0389

HB0389 compared with HB0389S01

moves all Department of Health and Human Services duties related to the medical cannabis program to UDAF;

- 18 ▶ allows medical cannabis processors to make cannabis products with a THC content below .3%
(low THC products);
- 20 ▶ allows medical cannabis pharmacies to sell low THC products; and
- 21 ▶ allows any patient to obtain a medical cannabis patient card from a recommending medical provider through a virtual visit.

Money Appropriated in this Bill:

26 None

Other Special Clauses:

28 None

Utah Code Sections Affected:

AMENDS:

31 **4-41-103.2** , as last amended by Laws of Utah 2025, Chapter 114

32 **4-41a-102** , as last amended by Laws of Utah 2025, First Special Session, Chapter 9

33 **4-41a-104** , as last amended by Coordination Clause, Laws of Utah 2023, Chapter 307 and enacted
by Laws of Utah 2018, Third Special Session, Chapter 1

35 **4-41a-201** , as last amended by **Laws of Utah 2025, Chapter 414**

36 **4-41a-201.1** , as last amended by Laws of Utah 2025, Chapter 414

37 **4-41a-204** , as last amended by **Laws of Utah 2025, First Special Session, Chapter 16**

38 **4-41a-602** , as last amended by Laws of Utah 2025, Chapter 392

39 **4-41a-801** , as last amended by **Laws of Utah 2025, Chapters 114, 414**

40 **26B-4-201** , as last amended by Laws of Utah 2025, Chapter 392

41 **26B-4-202** , as last amended by **Laws of Utah 2025, Chapter 392**

42 **26B-4-213** , as last amended by Laws of Utah 2025, Chapter 392

43 **26B-4-214** , as last amended by Laws of Utah 2025, Chapter 392

44 **26B-4-219** , as last amended by Laws of Utah 2025, Chapter 414

45 **26B-4-222** , as last amended by Laws of Utah 2025, First Special Session, Chapter 9

ENACTS:

47 **26B-4-201.1** , **Utah Code Annotated 1953**

RENUMBERS AND AMENDS:

HB0389 compared with HB0389S01

49 **4-41a-104.1** , (Renumbered from 26B-1-310, as last amended by Laws of Utah 2025, First Special
Session, Chapter 9)

51 **4-41a-111 , (Renumbered from 26B-1-435, as last amended by Laws of Utah 2025, First
Special Session, Chapter 9)**

53 *Be it enacted by the Legislature of the state of Utah:*

54 Section 1. Section **4-41-103.2** is amended to read:

55 **4-41-103.2. Cannabinoid processor license.**

56 (1) The department or a licensee of the department may process a cannabinoid product.

57 (2) A person seeking a cannabinoid processor license shall provide to the department:

58 (a) the legal description and global positioning coordinates sufficient for locating the facility the person
uses to process industrial hemp; and

59 (b) written consent allowing a representative of the department and local law enforcement to enter all
premises where the person processes or stores industrial hemp for the purpose of:

60 (i) conducting a physical inspection; or

61 (ii) ensuring compliance with the requirements of this chapter.

62 (3) The department may set a fee in accordance with Subsection 4-2-103(2) for the application for a
cannabinoid processor license.

63 (4) A licensee may only market a cannabinoid product that the licensee processes.

64 (5)

65 (a) An applicant for a cannabinoid processor license shall:

66 (i) be at least 18 years old; and

67 (ii) submit a nationwide criminal history from the Federal Bureau of Investigation to the
department.

68 (b) The department shall reject an individual's application for a cannabinoid processor license if the
criminal history described in Subsection (5)(a)(ii) was not completed in the previous 90 days before
the day the applicant submits the license application to the department.

69 (6) An applicant is not eligible to receive a cannabinoid processor license if the applicant has:

70 (a) been convicted of a felony; or

71 (b) been convicted of a drug-related misdemeanor within the previous 10 years.

HB0389 compared with HB0389S01

(7) A person licensed under Section 4-41a-201 as a cannabis processing facility as defined in Section 4-41a-102 may produce a cannabinoid product that complies with the requirements of this chapter without obtaining a license under this section.

84 Section 2. Section **4-41a-102** is amended to read:

85 **4-41a-102. Definitions.**

77 As used in this chapter:

77 (1) "Adulterant" means any poisonous or deleterious substance in a quantity that may be injurious to health, including:

79 (a) pesticides;

80 (b) heavy metals;

81 (c) solvents;

82 (d) microbial life;

83 (e) artificially derived cannabinoid;

84 (f) toxins; or

85 (g) foreign matter.

86 (2) "Advertise" or "advertising" means information provided by a person in any medium:

87 (a) to the public; and

88 (b) that is not age restricted to an individual who is at least 21 years old.

89 (3) "Advisory board" means the Medical Cannabis Policy Advisory Board created in Section

[26B-1-435] 4-41a-111.

91 (4)

93 (a) "Anticompetitive business practice" means any practice that is an illegal anticompetitive activity under Section 76-16-510.

94 (b) "Anticompetitive business practice" may include:

96 (i) agreements that may be considered unreasonable when competitors interact to the extent that they are:

97 (A) no longer acting independently; or

98 (B) when collaborating are able to wield market power together;

99 (ii) monopolizing or attempting to monopolize trade by:

100 (A) acting to maintain or acquire a dominant position in the market; or

100 (B) preventing new entry into the market; or

HB0389 compared with HB0389S01

101 (iii) other conduct outlined in rule.

102 (5)

105 (a) "Artificially derived cannabinoid" means a chemical substance that is created by a chemical reaction
that changes the molecular structure of any chemical substance derived from the cannabis plant.

106 (b) "Artificially derived cannabinoid" does not include:

108 (i) a naturally occurring chemical substance that is separated from the cannabis plant by a chemical or
mechanical extraction process; or

110 (ii) a cannabinoid that is produced by decarboxylation from a naturally occurring cannabinoid acid
without the use of a chemical catalyst.

112 (6) "Batch" means a quantity of:

114 (a) cannabis extract produced on a particular date and time and produced between completion of
equipment and facility sanitation protocols until the next required sanitation cycle during which lots
of cannabis are used;

117 (b) cannabis product produced on a particular date and time and produced between completion of
equipment and facility sanitation protocols until the next required sanitation cycle during which
cannabis extract is used; or

120 (c) cannabis flower packaged on a particular date and time and produced between completion of
equipment and facility sanitation protocols until the next required sanitation cycle during which lots
of cannabis are being used.

122 (7) "Cannabis Research Review Board" means the Cannabis Research Review Board created in Section
26B-1-420.

124 (8) "Cannabis" means the same as that term is defined in Section 26B-4-201.

126 (9) "Cannabis concentrate" means:

128 (a) the product of any chemical or physical process applied to naturally occurring biomass that
concentrates or isolates the cannabinoids contained in the biomass; and

130 (b) any amount of a natural cannabinoid or artificially derived cannabinoid in an artificially derived
cannabinoid's purified state.

132 (10) "Cannabis cultivation byproduct" means any portion of a cannabis plant that is not intended to be
sold as a cannabis plant product.

134 (11) "Cannabis cultivation facility" means a person that:

136 (a) possesses cannabis;

HB0389 compared with HB0389S01

132 (b) grows or intends to grow cannabis; and

133 (c) sells or intends to sell cannabis to a cannabis cultivation facility, a cannabis processing facility, or a medical cannabis research licensee.

135 (12) "Cannabis cultivation facility agent" means an individual who

136 holds a valid cannabis production establishment agent registration card with a cannabis cultivation facility designation.

138 (13) "Cannabis derivative product" means a product made using cannabis concentrate.

139 (14) "Cannabis plant product" means any portion of a cannabis plant intended to be sold in a form that is recognizable as a portion of a cannabis plant.

141 (15) "Cannabis processing facility" means a person that:

142 (a) acquires or intends to acquire cannabis from a cannabis production establishment;

143 (b) possesses cannabis with the intent to manufacture a cannabis product;

144 (c) manufactures or intends to manufacture a cannabis product from unprocessed cannabis or a cannabis extract; and

146 (d) sells or intends to sell a cannabis product to a medical cannabis pharmacy or a medical cannabis research licensee.

148 (16) "Cannabis processing facility agent" means an individual who

149 holds a valid cannabis production establishment agent registration card with a cannabis processing facility designation.

151 (17) "Cannabis product" means the same as that term is defined in Section 26B-4-201.

152 (18) "Cannabis production establishment" means a cannabis cultivation facility, a cannabis processing facility, or an independent cannabis testing laboratory.

154 (19) "Cannabis production establishment agent" means a cannabis cultivation facility agent, a cannabis processing facility agent, or an independent cannabis testing laboratory agent.

156 (20) "Cannabis production establishment agent registration card" means a registration card that the department issues that:

158 (a) authorizes an individual to act as a cannabis production establishment agent; and

159 (b) designates the type of cannabis production establishment for which an individual is authorized to act as an agent.

161 (21) "Closed-door medical cannabis pharmacy" means a facility operated by a home delivery medical cannabis pharmacy for delivering medical cannabis.

HB0389 compared with HB0389S01

163 (22) "Community location" means a public or private elementary or secondary school, a church, a
public library, a public playground, or a public park.

165 (23) "Cultivation space" means, quantified in square feet, the horizontal area in which a cannabis
cultivation facility cultivates cannabis, including each level of horizontal area if the cannabis
cultivation facility hangs, suspends, stacks, or otherwise positions plants above other plants in
multiple levels.

169 (24) "Delivery address" means:
170 (a) for a medical cannabis cardholder who is not a facility:
171 (i) the medical cannabis cardholder's home address; or
172 (ii) an address designated by the medical cannabis cardholder that:
173 (A) is the medical cannabis cardholder's workplace; and
174 (B) is not a community location; or
175 (b) for a medical cannabis cardholder that is a facility, the facility's address.

176 (25) "Department" means the Department of Agriculture and Food.

177 (26) "Family member" means a parent, step-parent, spouse, child, sibling, step-sibling, uncle, aunt,
nephew, niece, first cousin, mother-in-law, father-in-law, brother-in-law, sister-in-law, son-in-law,
daughter-in-law, grandparent, or grandchild.

180 (27) "Government issued photo identification" means the same as that term is defined in Section
26B-4-201, including expired identification in accordance with Section 26B-4-244.

183 (28) "Home delivery medical cannabis pharmacy" means a medical cannabis pharmacy that the
department authorizes, as part of the pharmacy's license, to deliver medical cannabis shipments to a
delivery address to fulfill electronic orders.

186 (29)
187 (a) "Independent cannabis testing laboratory" means a person that:
188 (i) conducts a chemical or other analysis of cannabis or a cannabis product; or
189 (ii) acquires, possesses, and transports cannabis or a cannabis product with the intent to conduct a
chemical or other analysis of the cannabis or cannabis product.

190 (b) "Independent cannabis testing laboratory" includes a laboratory that the department or a research
university operates in accordance with Subsection 4-41a-201(14).

192 (30) "Independent cannabis testing laboratory agent" means an individual who
193

HB0389 compared with HB0389S01

holds a valid cannabis production establishment agent registration card with an independent cannabis testing laboratory designation.

195 (31) "Inventory control system" means a system described in Section 4-41a-103.

196 (32) "Licensing board" or "board" means the ~~Cannabis Production Establishment and Pharmacy Licensing Advisory~~ Specialized Product Authority Licensing Board created in Section 4-41a-201.1.

199 (33) "Medical cannabis" or "medical cannabis product" means the same as that term is defined in Section 26B-4-201.

201 (34) "Medical cannabis card" means the same as that term is defined in Section 26B-4-201.

202 (35) "Medical cannabis courier" means a courier that:

203 (a) the department licenses in accordance with Section 4-41a-1201; and

204 (b) contracts with a home delivery medical cannabis pharmacy to deliver medical cannabis shipments to fulfill electronic orders.

206 (36) "Medical cannabis courier agent" means an individual who:

207 (a) is an employee of a medical cannabis courier; and

208 (b) who holds a valid medical cannabis courier agent registration card.

209 (37) "Medical cannabis pharmacy" means the same as that term is defined in Section 26B-4-201.

211 (38) "Medical cannabis pharmacy agent" means the same as that term is defined in Section 26B-4-201.

213 (39) "Medical cannabis research license" means a license that the department issues to a research university for the purpose of obtaining and possessing medical cannabis for academic research.

216 (40) "Medical cannabis research licensee" means a research university that the department licenses to obtain and possess medical cannabis for academic research, in accordance with Section 4-41a-901.

219 (41) "Medical cannabis shipment" means a shipment of medical cannabis that a home delivery medical cannabis pharmacy or a medical cannabis courier delivers to a delivery address to fulfill an electronic medical cannabis order.

222 (42) "Medical cannabis treatment" means the same as that term is defined in Section 26B-4-201.

224 (43) "Medicinal dosage form" means the same as that term is defined in Section 26B-4-201.

225 (44) "Patient product information insert" means the same as that term is defined in Section 26B-4-201.

227 (45) "Pharmacy ownership limit" means an amount equal to 30% of the total number of medical cannabis pharmacy licenses issued by the department rounded down to the nearest whole number.

230 (46) "Pharmacy medical provider" means the same as that term is defined in Section 26B-4-201.

232 (47) "Qualified Production Enterprise Fund" means the fund created in Section 4-41a-104.

HB0389 compared with HB0389S01

233 (48) "Recommending medical provider" means the same as that term is defined in Section 26B-4-201.

235 (49) "Research university" means the same as that term is defined in Section 53H-8-202 and a private,
nonprofit college or university in the state that:

237 (a) is accredited by the Northwest Commission on Colleges and Universities;

238 (b) grants doctoral degrees; and

239 (c) has a laboratory containing or a program researching a schedule I controlled substance described in
Section 58-37-4.

241 (50) "State electronic verification system" means the system described in Section 26B-4-202.

242 (51) "Targeted marketing" means the promotion of medical cannabis, a medical cannabis brand, or a
medical cannabis device using any of the following methods:

244 (a) electronic communication to an individual who is at least 21 years old and has requested to receive
promotional information;

246 (b) an in-person marketing event that is:

247 (i) held inside a medical cannabis pharmacy; and

248 (ii) in an area where only a medical cannabis cardholder may access the event;

249 (c) other marketing material that is physically available or digitally displayed in a medical cannabis
pharmacy; or

251 (d) a leaflet a medical cannabis pharmacy places in the opaque package or box that is provided to an
individual when obtaining medical cannabis:

253 (i) in the medical cannabis pharmacy;

254 (ii) at the medical cannabis pharmacy's drive-through pick up window; or

255 (iii) in a medical cannabis shipment.

256 (52) "Tetrahydrocannabinol" or "THC" means the same as that term is defined in Section 4-41-102.

258 (53) "Tier one cannabis processing facility" means a cannabis processing facility that is able to:

260 (a) create cannabis concentrate;

261 (b) create cannabis derivative product; and

262 (c) package and label medical cannabis.

263 (54) "Tier two cannabis processing facility" means a cannabis processing facility that is able to package
and label medical cannabis only if the medical cannabis is a cannabis plant product.

266 (55) "THC analog" means the same as that term is defined in Section 4-41-102.

267 (56) "Total composite tetrahydrocannabinol" means all detectable forms of tetrahydrocannabinol.

HB0389 compared with HB0389S01

269 (57) "Total tetrahydrocannabinol" or "total THC" means the same as that term is defined in Section
4-41-102.

281 Section 3. Section **4-41a-104** is amended to read:

4-41a-104. Qualified Production Enterprise Fund -- Creation -- Revenue neutrality.

274 (1) There is created an enterprise fund known as the "Qualified Production Enterprise Fund."

276 (2) The fund created in this section is funded from:

277 (a) money the department deposits into the fund under this chapter;

278 (b) appropriations the Legislature makes to the fund; [and]

279 (c) the interest described in Subsection (3)[.] ; and

280 (d) the fee described in Subsection (6).

281 (3) Interest earned on the Qualified Production Enterprise Fund shall be deposited into the fund.

283 (4) The department may [only]use money in the fund to fund the department's implementation of[this
chapter.] :

285 (a) this chapter;

286 (b) Chapter 41, Hemp and Cannabinoid Act; or

287 (c) Chapter 45, Kratom Consumer Protection Act.

288 (5) The department shall set fees authorized under this chapter in amounts that the department
anticipates are necessary, in total, to cover the department's cost to implement this chapter.

291 (6) The department may impose a uniform fee on each medical cannabis transaction in a medical
cannabis pharmacy in an amount that the department sets in accordance with Section 63J-1-504.

304 Section 4. Section **4-41a-104.1** is renumbered and amended to read:

**[26B-1-310] 4-41a-104.1. Qualified Patient Enterprise Fund -- Creation -- Revenue
neutrality -- Uniform fee.**

298 (1) There is created an enterprise fund known as the "Qualified Patient Enterprise Fund."

299 (2) The fund created in this section is funded from:

300 (a) money the {~~department{}~~ Department of Health and Human Services} deposits into the fund
under [Chapter 4, Part 2, Cannabinoid Research and Medical Cannabis] Title 26B, Chapter 4, Part 2,
Cannabinoid Research and Medical Cannabis;

303 (b) appropriations the Legislature makes to the fund; and

304 (c) the interest described in Subsection (3).

305 (3) Interest earned on the fund shall be deposited into the fund.

HB0389 compared with HB0389S01

306 (4) Money deposited into the fund may only be used by:

307 (a) the department to accomplish the department's responsibilities described in [Chapter 4, Part 2, Cannabinoid Research and Medical Cannabis] Title 26B, Chapter 4, Part 2, Cannabinoid Research and Medical Cannabis;

310 (b) the Center for Medical Cannabis Research created in Section 53H-4-206 to accomplish the Center for Medical Cannabis Research's responsibilities; and

312 (c) [the Department of Agriculture and Food for the one time purchase of equipment to meet the requirements described in Section 4-41a-204.1] expenses for employing the licensing board.

315 (5) The department shall set fees authorized under [Chapter 4, Part 2, Cannabinoid Research and Medical Cannabis] Title 26B, Chapter 4, Part 2, Cannabinoid Research and Medical Cannabis, in amounts that the department anticipates are necessary, in total, to cover the department's cost to implement [Chapter 4, Part 2, Cannabinoid Research and Medical Cannabis] Title 26B, Chapter 4, Part 2, Cannabinoid Research and Medical Cannabis.

321 (6) The department may impose a uniform fee on each medical cannabis transaction in a medical cannabis pharmacy in an amount that, subject to Subsection (5), the department sets in accordance with Section 63J-1-504.

334 Section 5. Section **4-41a-111** is renumbered and amended to read:

[26B-1-435]. Medical Cannabis Policy Advisory Board creation -- Membership -- Duties.

336 (1) There is created within the department the Medical Cannabis Policy Advisory Board.

339 (2)

340 (a) The advisory board shall consist of the following members:

341 [(i) appointed by the executive director:]

343 [(A) a recommending medical provider who has recommended medical cannabis to at least 100 patients before being appointed;]

344 [(B) a mental health specialist;]

346 [(C) an individual who represents an organization that advocates for medical cannabis patients;]

348 [(D) a member of the general public who holds a medical cannabis patient card; and]

349 [(E) a member of the general public who does not hold a medical cannabis card;]

350 (ii) (i) appointed by the commissioner of the Department of Agriculture and Food:

(A) an individual who owns or operates a licensed cannabis cultivation facility, as defined in Section 4-41a-102;

HB0389 compared with HB0389S01

352 (B) an individual who owns or operates a licensed medical cannabis pharmacy; [and]

354 (C) a law enforcement officer; [and]

355 (D) a recommending medical provider who has recommended medical cannabis to at least 100 patients
before being appointed;

357 (E) a mental health specialist;

358 (F) an individual who represents an organization that advocates for medical cannabis patients;

360 (G) a member of the general public who holds a medical cannabis patient card; and

361 (H) a member of the general public who does not hold a medical cannabis card; and

363 [(iii)] (ii) a representative from the Center for Medical Cannabis Research created in Section
53H-4-206, appointed by the Center for Medical Cannabis Research.

365 (b) The commissioner of the Department of Agriculture and Food shall ensure that at least one
individual appointed under Subsection [(2)(a)(ii)(A)] (2)(a)(i)(A) or (B) also owns or operates a
licensed cannabis processing facility.

368 (3)
(a) Subject to Subsection (3)(b), a member of the advisory board shall serve for a four year term.

370 (b) When appointing the initial membership of the advisory board, the executive director and the
commissioner of the Department of Agriculture and Food shall coordinate to appoint four advisory
board members to serve a term of two years to ensure that approximately half of the board is
appointed every two years.

374 (4)
(a) If an advisory board member is no longer able to serve as a member, a new member shall be
appointed in the same manner as the original appointment.

376 (b) A member appointed in accordance with Subsection (4)(a) shall serve for the remainder of the
unexpired term of the original appointment.

378 (5)
(a) A majority of the advisory board members constitutes a quorum.

379 (b) The action of a majority of a quorum constitutes an action of the advisory board.

380 (c) For a term lasting one year, the advisory board shall annually designate members of the advisory
board to serve as chair and vice-chair.

382 (d) When designating the chair and vice-chair, the advisory board shall ensure that at least one
individual described in Subsection (2)(a)(i)(D) through (H) is appointed as chair or vice-chair.

HB0389 compared with HB0389S01

385 (6) An advisory board member may not receive compensation or benefits for the member's service on
the advisory board but may receive per diem and reimbursement for travel expenses incurred as an
advisory board member in accordance with:
388 (a) Sections 63A-3-106 and 63A-3-107; and
389 (b) rules made by the Division of Finance pursuant to Sections 63A-3-106 and 63A-3-107.
391 (7) The department shall:
392 (a) provide staff support for the advisory board; and
393 (b) assist the advisory board in conducting meetings.
394 (8) The advisory board may recommend:
395 (a) to the department [~~or the Department of Agriculture and Food~~] changes to current or proposed
medical cannabis rules or statutes; and
397 (b) to the appropriate legislative committee whether the advisory board supports a change to medical
cannabis statutes.
399 (9) The advisory board shall:
400 (a) review any draft rule that is authorized under Title 26B, Chapter 4, Part 2, Cannabinoid Research
and Medical Cannabis, or [Title 4, Chapter 41a, Cannabis Production Establishments and
Pharmacies] this chapter;
403 (b) consult with the [~~Department of Agriculture and Food~~] department regarding the issuance of an
additional:
405 (i) cultivation facility license under Section 4-41a-205; or
406 (ii) pharmacy license under Section 4-41a-1005;
407 (c) consult with the department regarding cannabis patient education;
408 (d) consult regarding the reasonableness of any fees set by the department [~~or the Department of~~
~~Agriculture and Food~~] that pertain to the medical cannabis program; and
411 (e) consult regarding any issue pertaining to medical cannabis when asked by the department [~~or the~~
~~Department of Agriculture and Food~~].

413 Section 6. Section 4-41a-201 is amended to read:

414 **4-41a-201. Cannabis production establishment -- License.**

415 (1) Except as provided in Subsection (14), a person may not operate a cannabis production
establishment without a license that the department issues under this chapter.
417 (2)

HB0389 compared with HB0389S01

421 (a)

422 (i) Subject to Subsections (6), (7), (8), and (13) and to Section 4-41a-205, for a licensing process
423 that the department initiates after March 17, 2021, the department, through the licensing board,
424 shall issue licenses in accordance with Section 4-41a-201.1.

425 (ii) In accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, the department
426 shall make rules to specify a transparent and efficient process to:

427 (A) solicit applications for a license under this section;
428 (B) allow for comments and questions in the development of applications;
429 (C) timely and objectively evaluate applications;
430 (D) hold public hearings that the department deems appropriate; and
431 (E) select applicants to receive a license.

432 (iii) The department may not issue a license to operate a cannabis production establishment to an
433 applicant who is not eligible for a license under this section.

434 (b) An applicant is eligible for a license under this section if the applicant submits to the licensing
435 board:

436 (i) subject to Subsection (2)(c), a proposed name and each address, located in a zone described in
437 Subsection 4-41a-406(2)(a) or (b), where the applicant will operate the cannabis production
438 establishment;

439 (ii) the name and address of any individual who has:

440 (A) for a publicly traded company, a financial or voting interest of 10% or greater in the proposed
441 cannabis production establishment;

442 (B) for a privately held company, a financial or voting interest in the proposed cannabis production
443 establishment; or

444 (C) the power to direct or cause the management or control of a proposed cannabis production
445 establishment;

446 (iii) an operating plan that:

447 (A) complies with Section 4-41a-204;

448 (B) includes operating procedures that comply with this chapter and any law the municipality or county
449 in which the person is located adopts that is consistent with Section 4-41a-406; and

450 (C) the department or licensing board approves;

HB0389 compared with HB0389S01

(iv) a statement that the applicant will obtain and maintain a liquid cash account with a financial institution or a performance bond that a surety authorized to transact surety business in the state issues in an amount of at least:

451 (A) \$100,000 for each cannabis cultivation facility for which the applicant applies; or

453 (B) \$50,000 for each cannabis processing facility or independent cannabis testing laboratory for which the applicant applies;

455 (v) an application fee in an amount that, subject to Subsection 4-41a-104(5), the department sets in accordance with Section 63J-1-504; and

457 (vi) a description of any investigation or adverse action taken by any licensing jurisdiction, government agency, law enforcement agency, or court in any state for any violation or detrimental conduct in relation to any of the applicant's cannabis-related operations or businesses.

461 (c)

462 (i) A person may not locate a cannabis production establishment:

463 (A) within 1,000 feet of a community location; or

465 (B) in or within 600 feet of a district that the relevant municipality or county has zoned as primarily residential.

469 (ii) The proximity requirements described in Subsection (2)(c)(i) shall be measured from the nearest entrance to the cannabis production establishment by following the shortest route of ordinary pedestrian travel to the property boundary of the community location or residential area.

473 (iii) The licensing board may grant a waiver to reduce the proximity requirements in Subsection (2)(c)

475 (i) by up to 20% if the licensing board determines that it is not reasonably feasible for the applicant to site the proposed cannabis production establishment without the waiver.

477 (iv) An applicant for a license under this section shall provide evidence of compliance with the proximity requirements described in Subsection (2)(c)(i).

479 (3) If the licensing board approves an application for a license under this section and Section 4-41a-201.1:

481 (a) the applicant shall pay the department an initial license fee in an amount that, subject to Subsection 4-41a-104(5), the department sets in accordance with Section 63J-1-504; and

483 (b) the department shall notify the Department of Public Safety of the license approval and the names of each individual described in Subsection (2)(b)(ii).

485 (4)

HB0389 compared with HB0389S01

(a) Except as provided in this Subsection (4), a cannabis production establishment shall obtain a separate license for each type of cannabis production establishment and each location of a cannabis production establishment.

(b) The licensing board may issue a cannabis cultivation facility license and a cannabis processing facility license to a person to operate at the same physical location or at separate physical locations.

(c) A cannabis cultivation facility may operate at [two] three addresses under a single license.

(d) A tier one cannabis processing facility may operate at a second address under the same tier one license if:

(i) the second address is co-located at a cannabis cultivation facility operated by the same licensee; and

(ii) the licensee pays a fee of \$70,000 for the second location.

(e) An applicant for a tier two cannabis processing facility license that has a cannabis cultivation facility license and intends to process cannabis at the cannabis cultivation facility shall pay a fee of \$25,000 for the tier two cannabis processing facility license.

(5) If the licensing board receives more than one application for a cannabis production establishment within the same city or town, the licensing board shall consult with the local land use authority before approving any of the applications pertaining to that city or town.

(6) The licensing board may not issue a license to operate an independent cannabis testing laboratory to a person who:

(a) holds a license or has an ownership interest in a medical cannabis pharmacy, a cannabis processing facility, or a cannabis cultivation facility;

(b) has an owner, officer, director, or employee whose family member holds a license or has an ownership interest in a medical cannabis pharmacy, a cannabis processing facility, or a cannabis cultivation facility; or

(c) proposes to operate the independent cannabis testing laboratory at the same physical location as a medical cannabis pharmacy, a cannabis processing facility, or a cannabis cultivation facility.

(7) The licensing board may not issue a license to operate a cannabis production establishment to an applicant if any individual described in Subsection (2)(b)(ii):

(a) has been convicted under state or federal law of:

(i) a felony in the preceding 10 years; or

(ii) after December 3, 2018, a misdemeanor for drug distribution;

(b) is younger than 21 years old; or

HB0389 compared with HB0389S01

518 (c) after September 23, 2019, until January 1, 2023, is actively serving as a legislator.

519 (8)

523 (a) If an applicant for a cannabis production establishment license under this section holds a license under [Title 4], Chapter 41, Hemp and Cannabinoid Act, the licensing board may not give preference to the applicant based on the applicant's status as a holder of the license.

527 (b) If an applicant for a license to operate a cannabis cultivation facility under this section holds a license to operate a medical cannabis pharmacy under this title, the licensing board may give consideration to the applicant based on the applicant's status as a holder of a medical cannabis pharmacy license if:

530 (i) the applicant demonstrates that a decrease in costs to patients is more likely to result from the applicant's vertical integration than from a more competitive marketplace; and

532 (ii) the licensing board finds multiple other factors, in addition to the existing license, that support granting the new license.

533 (9) The licensing board may revoke a license under this part:

536 (a) if the cannabis production establishment does not begin cannabis production operations within one year after the day on which the licensing board issues the initial license;

538 (b) after the third of the same violation of this chapter in any of the licensee's licensed cannabis production establishments or medical cannabis pharmacies;

540 (c) if any individual described in Subsection (2)(b) is convicted, while the license is active, under state or federal law of:

541 (i) a felony; or

542 (ii) after December 3, 2018, a misdemeanor for drug distribution;

547 (d) if the licensee fails to provide the information described in Subsection (2)(b)(vi) at the time of application, or fails to supplement the information described in Subsection (2)(b)(vi) with any investigation or adverse action that occurs after the submission of the application within 14 calendar days after the licensee receives notice of the investigation or adverse action;

550 (e) if the cannabis production establishment demonstrates a willful or reckless disregard for the requirements of this chapter or the rules the department makes in accordance with this chapter;

550 (f) if, after a change of ownership described in Subsection (15)(b), the board determines that the cannabis production establishment no longer meets the minimum standards for licensure and operation of the cannabis production establishment described in this chapter;

HB0389 compared with HB0389S01

554 (g) for an independent cannabis testing laboratory, if the independent cannabis testing laboratory fails to
substantially meet the performance standards described in Subsection (14)(b); or

557 (h) if, following an investigation conducted pursuant to Subsection 4-41a-201.1(11), the board finds
that the licensee has participated in an anticompetitive business practice.

559 (10)

564 (a) A person who receives a cannabis production establishment license under this chapter, if the
municipality or county where the licensed cannabis production establishment will be located
requires a local land use permit, shall submit to the licensing board a copy of the licensee's approved
application for the land use permit within 120 days after the day on which the licensing board issues
the license.

567 (b) If a licensee fails to submit to the licensing board a copy of the licensee's approved land use permit
application in accordance with Subsection (10)(a), the licensing board may revoke the licensee's
license.

569 (11) The department shall deposit the proceeds of a fee that the department imposes under this section
into the Qualified Production Enterprise Fund.

571 (12) The department shall begin accepting applications under this part on or before January 1, 2020.

573 (13)

575 (a) The department's authority, and consequently the licensing board's authority, to issue a license under
this section is plenary and is not subject to review.

576 (b) Notwithstanding Subsection [(2)(a)(ii)(A)] (2)(a)(ii), the decision of the department to award a
license to an applicant is not subject to:

577 (i) Title 63G, Chapter 6a, Part 16, Protests; or

578 (ii) Title 63G, Chapter 6a, Part 17, Procurement Appeals Board.

577 (14)

578 (a) Notwithstanding this section, the department:

580 (i) may operate or partner with a research university to operate an independent cannabis testing
laboratory;

(ii) if the department operates or partners with a research university to operate an independent
cannabis testing laboratory, may not cease operating or partnering with a research university to
operate the independent cannabis testing laboratory unless:

584 (A) the department issues at least two licenses to independent cannabis testing laboratories; and

HB0389 compared with HB0389S01

586 (B) the department has ensured that the licensed independent cannabis testing laboratories have
587 sufficient capacity to provide the testing necessary to support the state's medical cannabis market;
588 and
589 (iii) after ceasing department or research university operations under Subsection (14)(a)(ii) shall
590 resume independent cannabis testing laboratory operations at any time if:
591 (A) fewer than two licensed independent cannabis testing laboratories are operating; or
592 (B) the licensed independent cannabis testing laboratories become, in the department's determination,
593 unable to fully meet the market demand for testing.

596 (b)

597 (i) The department shall make rules, in accordance with Title 63G, Chapter 3, Utah Administrative
598 Rulemaking Act, to establish performance standards for the operation of an independent cannabis
599 testing laboratory, including deadlines for testing completion.

600 (ii) A license that the department issues to an independent cannabis testing laboratory is contingent
601 upon substantial satisfaction of the performance standards described in Subsection (14)(b)(i), as
602 determined by the board.

603 (15)

604 (a) A cannabis production establishment license is not transferrable or assignable.

605 (b) If the ownership of a cannabis production establishment changes by 50% or more:
606 (i) the cannabis production establishment shall submit a new application described in Subsection (2)(b),
607 subject to Subsection (2)(c);
608 (ii) within 30 days of the submission of the application, the board shall:
609 (A) conduct the application review described in Section 4-41a-201.1; and
610 (B) award a license to the cannabis production establishment for the remainder of the term of the
611 cannabis production establishment's license before the ownership change if the cannabis production
612 establishment meets the minimum standards for licensure and operation of the cannabis production
613 establishment described in this chapter; and
614 (iii) if the board approves the license application, notwithstanding Subsection (3), the cannabis
615 production establishment shall pay a license fee that the department sets in accordance with Section
616 63J-1-504 in an amount that covers the board's cost of conducting the application review.

618 Section 7. Section **4-41a-201.1** is amended to read:

619 **4-41a-201.1. Specialized Product Authority Licensing Board -- Composition -- Duties.**

HB0389 compared with HB0389S01

327 (1) There is created within the department the [Cannabis Production Establishment and Pharmacy
328 Licensing Advisory] Specialized Product Authority Licensing Board.

329 (2) The commissioner shall [;]
330 [(a) appoint the { } members { } directors } of] hire three directors as employees of the department to be
331 on the licensing board [;]
332 [(b) submit the name of each individual that the commissioner appoints under Subsection (2)(a) to the
333 governor for confirmation or rejection; and]
334 [(e) if the governor rejects an appointee that the commissioner submits under Subsection (2)(b), appoint
335 another individual in accordance with this Subsection (2).]
336 (3)
337 (a) [Except as provided in Subsection (3)(b), the] The licensing board shall consist of [the following
338 eight members:] three directors.
339 [(i) the following seven voting members whom the commissioner appoints:]
340 [(A) one member of the public:]
341 [(B) one member with knowledge and experience in the pharmaceutical or nutraceutical manufacturing
342 industry:]
343 [(C) one member representing law enforcement:]
344 [(D) one member whom an organization representing medical cannabis patients recommends:]
345 [(E) a chemist who has experience with cannabis and who is associated with a research university:]
346 [(F) a pharmacist who is not associated with the medical cannabis industry; and]
347 [(G) an accountant; and]
348 [(ii) the commissioner or the commissioner's designee as a non-voting member, except to cast a
349 deciding vote in the event of a tie.]
350 [(b) The commissioner may appoint a ninth member to the licensing board who has a background in the
351 cannabis cultivation and processing industry.]
352 [(e) The commissioner or the commissioner's designee shall serve as the chair of the licensing board.]
353 [(d)] (b) An individual is not eligible [for appointment to be a member] as a director of the licensing
354 board if the individual:
355 (i) has any commercial or ownership interest in a cannabis production establishment, medical cannabis
356 pharmacy, or medical cannabis courier;
357

HB0389 compared with HB0389S01

(ii) has an owner, officer, director, or employee whose family member holds a license or has an ownership interest in a cannabis production establishment, medical cannabis pharmacy, or medical cannabis courier; or

361 (iii) is employed or contracted to lobby on behalf of any cannabis production establishment, medical cannabis pharmacy, or medical cannabis courier.

658 (c) At least one member of the licensing board shall have experience related to public health or medicine.

363 [(4)]

~~{f(a)} Except as provided in Subsektion (4)(b), a voting licensing board member shall serve a term of four years, beginning July 1 and ending June 30.]~~

365 [(b) Notwithstanding Subsection (4)(a), for the initial appointments to the licensing board, the commissioner shall stagger the length of the terms of licensing board members to ensure that the commissioner appoints two or three licensing board members every two years.]

369 [(e) As a licensing board member's term expires:]

370 ~~[(i) the licensing board member is eligible for reappointment; and]~~

371 ~~[(ii) the commissioner shall make an appointment, in accordance with Subsection (2), for the new term before the end of the member's term.]~~

373 ~~[(d) When a vacancy occurs on the licensing board for any reason other than the expiration of a licensing board member's term, the commissioner shall appoint a replacement to the vacant position, in accordance with Subsection (2), for the unexpired term.]~~

377 ~~[(e) In making appointments, the commissioner shall ensure that no two members of the licensing board are employed by or represent the same company or nonprofit organization.]~~

380 ~~[(f) The commissioner may remove a licensing board member for cause, neglect of duty, inefficiency, or malfeasance]~~

679 (4) A director may only be terminated for just cause, including inefficiency, incompetency, failure to maintain skills or adequate performance levels, insubordination, disloyalty to the orders of a superior, misfeasance, malfeasance, or nonfeasance.

385 (5)

(a)

[(i) {f} Five-] Two members of the licensing board constitute a quorum of the licensing board.

387

HB0389 compared with HB0389S01

[(ii) (b) An action of the majority of the licensing board members when a quorum is present constitutes an action of the licensing board.

389 [**(b)** The department shall provide staff support to the licensing board.]

390 [**(e)** A member of the licensing board may not receive compensation or benefits for the member's service, but may receive per diem and travel expenses in accordance with:]

392 [**(i)** Section 63A-3-106;]

393 [**(ii)** Section 63A-3-107; and]

394 [**(iii)** rules made by the Division of Finance in accordance with Sections 63A-3-106 and 63A-3-107.]

396 (6) The licensing board shall:

397 (a) [meet as called by the chair to]review cannabis production establishment, medical cannabis pharmacy, and medical cannabis courier license applications;

399 (b) review each license application for compliance with:

400 (i) this chapter; and

401 (ii) department rules;

402 (c) conduct a public hearing to consider the license application;

403 (d) approve the department's license application forms and checklists; and

404 (e) make a determination on each license application.

405 (7) The licensing board shall hold a public hearing to review a cannabis production establishment's or medical cannabis pharmacy's license if the establishment:

407 (a) changes ownership by an interest of 20% or more;

408 (b) changes or adds a location;

409 (c) upgrades to a different licensing tier under department rule;

410 (d) changes extraction or formulation standard operating procedures;

411 (e) adds an industrial hemp processing or cultivation [~~hiense~~] operation to the same location as the cannabis production establishment's processing facility; or

413 (f) as necessary based on the recommendation of the department.

414 (8) In a public hearing held under Subsection (7), the licensing board may consider the following in determining whether to approve a request to change pharmacy locations:

416 (a) medical cannabis availability, quality, and variety;

417 (b) whether geographic dispersal among licensees is sufficient to reasonably maximize access to the largest number of medical cannabis cardholders;

HB0389 compared with HB0389S01

419 (c) the extent to which the pharmacy can increase efficiency and reduce the cost to patients of medical
420 cannabis; and

421 (d) the factors listed in Subsection 4-41a-1004(7).

422 (9) In a public hearing held pursuant to Subsection (7), the licensing board may not approve a request to
423 change a medical cannabis pharmacy location outside of the pharmacy's current region established
424 under Subsection 4-41a-1005(1)(c)(ii)(A).

425 (10)

426 (a) The licensing board shall meet as necessary to consider cannabis production establishment, medical
427 cannabis pharmacy, and medical cannabis courier license renewal applications.

428 (b) During the meeting described in Subsection (10)(a):

429 (i) a representative from each applicant for renewal shall:

430 (A) attend in person or electronically; or

431 (B) submit information before the meeting, as the licensing board may require, for the licensing board's
432 consideration;

433 (ii) the licensing board shall consider, for each cannabis cultivation facility seeking renewal,
434 information including:

435 (A) the amount of biomass the licensee produced during the current calendar year;

436 (B) the amount of biomass the licensee projects to produce during the following year;

437 (C) the amount of hemp waste the licensee currently holds;

438 (D) the current square footage or acres of growing area the licensee uses; and

439 (E) the square footage or acres of growing area the licensee projects to use in the following year;

440 (iii) the licensing board shall consider, for each cannabis processing facility seeking renewal,
441 information including:

442 (A) methods and procedures for extraction;

443 (B) standard operating procedures; and

444 (C) a complete listing of the medical dosage forms that the licensee produces; and

445 (iv) the licensing board shall consider, for each cannabis pharmacy seeking renewal, information
446 including:

447 (A) product availability, quality, and variety;

448 (B) the pharmacy's operating procedures and practices; and

449 (C) the factors listed in Subsection 4-41a-1003(1).

HB0389 compared with HB0389S01

452 (c) Following consideration of the information provided under Subsection (10)(b), the licensing board
may elect to approve, deny, or issue conditional approval of a cannabis production establishment or
pharmacy license renewal application.

455 (d) The information a licensee or license applicant provides to the licensing board for a license
determination constitutes a protected record under Subsection 63G-2-305(1) or (2) if the applicant
or licensee provides the licensing board with the information regarding business confidentiality
required in Section 63G-2-309.

459 (11)
(a) In cooperation with the attorney general, the licensing board may investigate information received
by the department indicating that a licensee is potentially engaging in anticompetitive business
practices.

462 (b) In investigating potential anticompetitive business practices under this section, the attorney general
may issue civil investigative demands as set forth in Section 76-16-506.

465 ~~[(12) The department shall:~~
~~[(a) provide staff support for the licensing board;]~~
~~[(b) assist the licensing board in conducting meetings; and]~~
~~[(c) review all submitted applications for completion and accuracy.]~~

469 ~~(13){(12)}~~
(a) ~~The licensing board shall hear all appeals related to administrative action taken under this chapter,
Chapter 41, Hemp and Cannabinoid Act, and Chapter 45, Kratom Consumer Protection Act, as an
informal proceeding under Title 63G, Chapter 4, Administrative Procedures Act.~~
(b) ~~The licensing board shall create rules for hearing appeals in accordance with Title 63G, Chapter 3,
Utah Administrative Rulemaking Act.~~

772 ~~(13)~~
475 ~~(14){(a)} The licensing board in consultation with the Compassionate Use Board described in Section
26B-1-421 shall provide recommendations, if any, to the Medical Cannabis Governance Structure
Working Group regarding additional conditions to be added to the qualifying conditions list
described in Section 26B-4-203.~~
776 ~~(b) The licensing board shall create a process that allows the public to suggest conditions that should be
recommended to the Legislature for inclusion on the qualifying conditions list.~~

479

HB0389 compared with HB0389S01

(15){(14)} For rules made under this chapter, the department shall collaborate with the licensing board when making the rules.

781 (15) The licensing board shall supervise and assist the department in carrying out the duties described in
782 Title 26B, Chapter 4, Part 2, Cannabinoid Research and Medical Cannabis.

783 Section 8. Section 4-41a-204 is amended to read:

4-41a-204. Operating plan.

785 (1) A person applying for a cannabis production establishment license or license renewal shall submit to the department for the department's review a proposed operating plan that complies with this section and that includes:

788 (a) a description of the physical characteristics of each proposed facility, including a floor plan and an architectural elevation;

790 (b) a description of the credentials and experience of:

791 (i) each officer, director, and owner of the proposed cannabis production establishment; and

793 (ii) any highly skilled or experienced prospective employee;

794 (c) the cannabis production establishment's employee training standards;

795 (d) a security plan;

796 (e) a description of the cannabis production establishment's inventory control system, including a description of how the inventory control system is compatible with the state electronic verification system described in Section 26B-4-202;

799 (f) storage protocols, both short- and long-term, to ensure that cannabis is stored in a manner that is sanitary and preserves the integrity of the cannabis;

801 (g) for a cannabis cultivation facility, the information described in Subsection (2);

802 (h) for a cannabis processing facility, the information described in Subsection (3);

803 (i) for an independent cannabis testing laboratory, the information described in Subsection (4); and

805 (j) for a cannabis production establishment located in an industrial zone, a plan to reduce odor created by the cannabis production establishment that:

807 (i) meets local ordinance nuisance laws; and

808 (ii) identifies:

809 (A) operations and materials that generate odors; and

810 (B) equipment, operations, or materials the cannabis production establishment will use to mitigate odor emissions, including plans to maintain equipment.

HB0389 compared with HB0389S01

812 (2)

814 (a) A cannabis cultivation facility shall ensure that the facility's operating plan includes the facility's intended:

816 (i) cannabis cultivation practices, including the facility's intended pesticide use and plant food use; and

818 (ii) subject to Subsection (2)(b), acreage or square footage under cultivation and anticipated cannabis yield.

820 (b) Except as provided in Subsection (2)(c)(i) or (c)(ii), a cannabis cultivation facility may not:

822 (i) for a facility that cultivates cannabis only indoors, use more than 100,000 total square feet of cultivation space;

824 (ii) for a facility that cultivates cannabis only outdoors, use more than four acres for cultivation; and

828 (iii) for a facility that cultivates cannabis through a combination of indoor and outdoor cultivation, use more combined indoor square footage and outdoor acreage than allowed under the department's formula described in Subsection (2)(e).

829 (c)

831 (i) Each licensee may apply to the department for:

833 (A) a one-time, permanent increase of up to 20% of the limitation on the cannabis cultivation facility's cultivation space; or

835 (B) a short-term increase, not to exceed 12 months, of up to 40% of the limitation on the cannabis cultivation facility's cultivation space.

837 (ii) After conducting a review equivalent to the review described in Subsection 4-41a-205(2)(a), if the department determines that additional cultivation is needed, the department may:

839 (A) grant the one-time, permanent increase described in Subsection (2)(c)(i)(A); or

841 (B) grant the short-term increase described in Subsection (2)(c)(i)(B).

843 (d) If a licensee describes an intended acreage or square footage under cultivation under Subsection (2)(a)(ii) that is less than the limitation described in Subsection (2)(b), the licensee may not cultivate more than the licensee's identified intended acreage or square footage under cultivation.

845 (e) The department shall, in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, establish a formula for combined usage of indoor and outdoor cultivation that:

847 (i) does not exceed, in estimated cultivation yield, the aggregate limitations described in Subsection (2)(b)(i) or (ii); and

HB0389 compared with HB0389S01

847 (ii) allows a cannabis cultivation facility to operate both indoors and outdoors.

848 (f)

849 (i) The department may authorize a cannabis cultivation facility to operate at no more than [two] three
850 separate locations.

851 (ii) If the department authorizes multiple locations under Subsection (2)(f)(i)[,] :

852 (A) [-]the [two] multiple cannabis cultivation facility locations combined may not exceed the cultivation
853 limitations described in this Subsection (2)[.] ; and

854 (B) the cannabis cultivation facility shall pay a \$15,000 fee for each location after the second location.

855 (3) A cannabis processing facility's operating plan shall include the facility's intended cannabis
856 processing practices, including the cannabis processing facility's intended:

857 (a) offered variety of cannabis product;

858 (b) cannabinoid extraction method;

859 (c) cannabinoid extraction equipment;

860 (d) processing equipment;

861 (e) processing techniques; and

862 (f) sanitation and manufacturing safety procedures for items for human consumption.

863 (4) An independent cannabis testing laboratory's operating plan shall include the laboratory's intended:

864 (a) cannabis and cannabis product testing capability;

865 (b) cannabis and cannabis product testing equipment; and

866 (c) testing methods, standards, practices, and procedures for testing cannabis and cannabis products.

867 (5) Notwithstanding an applicant's proposed operating plan, a cannabis production establishment is
868 subject to land use regulations implemented by a local land use authority under Title 10, Chapter
869 20, Municipal Land Use, Development, and Management Act, or Title 17, Chapter 79, County Land
Use, Development, and Management Act, regarding the availability of outdoor cultivation in an
industrial zone.

870 Section 9. Section **4-41a-602** is amended to read:

4-41a-602. Cannabis product -- Labeling and child-resistant packaging.

871 (1) For any cannabis product that a cannabis processing facility processes or produces and for any raw
872 cannabis that the facility packages, the facility shall:

873 (a) label the cannabis or cannabis product with a label that:

874 (i) clearly and unambiguously states that the cannabis product or package contains cannabis;

HB0389 compared with HB0389S01

488 (ii) clearly displays the amount of total composite tetrahydrocannabinol, cannabidiol, and any known
cannabinoid that is greater than 1% of the total cannabinoids contained in the cannabis or cannabis
product as determined under Subsection 4-41a-701(4);

492 (iii) has a unique identification number that:
493 (A) is connected to the inventory control system; and
494 (B) identifies the unique cannabis product manufacturing process the cannabis processing facility used
to manufacture the cannabis product;

496 (iv) identifies the cannabinoid extraction process that the cannabis processing facility used to create the
cannabis product;

498 (v) does not display an image, word, or phrase that the facility knows or should know appeals to
children; and

500 (vi) discloses each active or potentially active ingredient, in order of prominence, and possible allergen;
and

502 (b) package the raw cannabis or cannabis product in a medicinal dosage form in a container that:
504 (i) is tamper evident and tamper resistant;
505 (ii) does not appeal to children;
506 (iii) does not mimic a candy container;
507 (iv) complies with child-resistant effectiveness standards that the United States Consumer Product
Safety Commission establishes;

509 (v) includes a warning label that states:
510 (A) for a container labeled on or after January 1, 2024, "WARNING: Cannabis has intoxicating effects,
may be addictive, and may increase risk of mental illness. Do not operate a vehicle or machinery
under its influence. KEEP OUT OF REACH OF CHILDREN. This product is for medical use only.
Use only as directed by a recommending medical provider."; or

515 (B) for a container labeled on or after January 1, 2026, "WARNING: Cannabis use by pregnant or
breastfeeding women, may result in fetal injury, preterm birth, or developmental problems for the
child. Cannabis may be addictive and may increase risk of mental illness. Do not operate a vehicle
or machinery under its influence. KEEP OUT OF REACH OF CHILDREN. This product is for
medical use only. Use only as directed by a recommending medical provider."; and

522 (vi) for raw cannabis or a cannabis product sold in a vaporizer cartridge labeled on or after May 3,
2023, includes a warning label that states:

HB0389 compared with HB0389S01

524 (A) "WARNING: Vaping of cannabis-derived products has been associated with lung injury.>"; and
526 (B) "WARNING: Inhalation of cannabis smoke has been associated with lung injury.".
528 (2) To ensure that a cannabis product that a cannabis processing facility processes or produces has a medical rather than recreational disposition, the facility may not produce or process a product whose logo, product name, or brand name includes terms related to recreational marijuana, including "weed," "pot," "reefer," "grass," "hash," "ganja," "Mary Jane," "high," "haze," "stoned," "joint," "bud," "smoke," "euphoria," "dank," "doobie," "kush," "frost," "cookies," "rec," "bake," "blunt," "combust," "bong," "budtender," "dab," "blaze," "toke," or "420."
535 (3) For any cannabis or cannabis product that the cannabis processing facility processes into a gelatinous cube, gelatinous rectangular cuboid, or lozenge in a cube or rectangular cuboid shape, the facility shall:
538 (a) ensure that the label described in Subsection (1)(a) does not contain a photograph or other image of the content of the container; and
540 (b) include on the label described in Subsection (1)(a) a warning about the risks of over-consumption.
542 (4) For any cannabis product that contains an artificially derived cannabinoid, the cannabis processing facility shall ensure that the label clearly:
544 (a) identifies each artificially derived cannabinoid; and
545 (b) identifies that each artificially derived cannabinoid is an artificially derived cannabinoid.
547 (5)
548 (a) A cannabis processor may not distribute medical cannabis with a label, logo, brand name, or in packaging if the label, logo, brand name, or packaging has not been pre-approved by the department.
550 (b) If the department has approved a label or packaging, a cannabis processor may change the approved label or packaging and use the changed label or packaging for use with another medical cannabis product without obtaining the department's approval if:
552 (i) the label or packaging complies with the requirements of this chapter and rules made under this chapter;
556 (ii) the only change to the label and packaging are changes to one or more of the following:
558 (A) flavor information;
559 (B) terpene information; or
560 (C) cultivar information; and

HB0389 compared with HB0389S01

561 (iii) no other changes were made to the label or package including graphics, fonts, sizing, or colors.

563 [571] (6) In accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, the
department:

565 (a) shall make rules to establish:

566 (i) a standard labeling format that:

567 (A) complies with the requirements of this section; and

568 (B) ensures inclusion of a pharmacy label; and

569 (ii) additional requirements on packaging for cannabis and cannabis products to ensure safety and
product quality; and

571 (b) may make rules to further define standards regarding images, words, phrases, or containers that may
appeal to children under Subsection (1)(a)(v) or (1)(b)(ii).

966 **Section 10. Section 4-41a-801 is amended to read:**

4-41a-801. Enforcement -- Fine -- Citation.

968 (1)

971 (a) If a person that is a cannabis production establishment, a cannabis production establishment agent,
a medical cannabis pharmacy, a medical cannabis pharmacy agent, or a medical cannabis courier,
violates this chapter, the department may:

972 (i) revoke the person's license or agent registration card;

973 (ii) decline to renew the person's license or agent registration card;

976 (iii) assess the person an administrative penalty that the department establishes by rule in
accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act; or

977 (iv) provide a letter of concern in accordance with Subsection (8).

980 (b) Except for a violation that threatens public health or for the third violation of the same rule or
statute in a 24-month period, the department shall issue a letter of concern before taking other
administrative action under this section.

982 (2) The department shall deposit an administrative penalty imposed under this section into the General
Fund.

(3)

(a) The department may take an action described in Subsection (3)(b) if the department concludes, upon
investigation, that, for a person that is a cannabis production establishment, a cannabis production

HB0389 compared with HB0389S01

establishment agent, a medical cannabis pharmacy, a medical cannabis pharmacy agent, or a medical cannabis courier:

987 (i) the person has violated the provisions of this chapter, a rule made under this chapter, or an order
issued under this chapter; or.

989 (ii) the person produced cannabis or a cannabis product batch that contains a substance, other than
cannabis, that poses a significant threat to human health.

991 (b) If the department makes the determination about a person described in Subsection (3)(a), the
department may:

993 (i) issue the person a written administrative citation;

994 (ii) attempt to negotiate a stipulated settlement;

995 (iii) order the person to cease and desist from the action that creates a violation; or

996 (iv) direct the person to appear before an adjudicative proceeding conducted under Title 63G, Chapter
4, Administrative Procedures Act.

998 (c) If the department concludes, upon investigation, that a cannabis production establishment or a
cannabis production establishment agent has produced a cannabis batch or a cannabis product batch
that contains a substance that poses a significant threat to human health, the department shall seize,
embargo, or destroy the cannabis batch or cannabis product batch.

1003 (4) The department may, for a person subject to an uncontested citation, a stipulated settlement, or a
finding of a violation in an adjudicative proceeding under this section, for a fine amount not already
specified in law, assess the person, who is not an individual, a fine of up to \$5,000 per violation,
in accordance with a fine schedule that the department establishes by rule in accordance with Title
63G, Chapter 3, Utah Administrative Rulemaking Act.

1009 (5) The department may not revoke a license without first directing the licensee to appear before an
adjudicative proceeding conducted under Title 63G, Chapter 4, Administrative Procedures Act.

1012 (6) If within 30 calendar days after the day on which a department serves a citation for a violation of
this chapter, the person that is the subject of the citation fails to request a hearing to contest the
citation, the citation becomes the department's final order.

1015 (7) The department may, for a person who fails to comply with a citation under this section:

1016 (a) refuse to issue or renew the person's license or agent registration card; or

1017 (b) suspend, revoke, or place on probation the person's license or registration card.

1018 (8)

HB0389 compared with HB0389S01

(a) A letter of concern shall describe:

- (i) the violation including the statute or rule being violated;
- (ii) possible options to remedy the issue; and
- (iii) possible consequences for not remedying the violation.

(b) Under a letter of concern, the department shall provide the person at least 30 days to remedy the violation.

(c) If the person fails to remedy the violation described in a letter of concern, the department may take other enforcement action as described in this section.

(d) If a letter of concern is resolved without an enforcement action being taken under Subsection (8)(c), the department may not report that a letter of concern was issued to the licensing board.

(9)

- (a) Except where a criminal penalty is expressly provided for a specific violation of this chapter, or where civil and criminal penalties are provided for violations of Section 76-10-31, if an individual:
 - (i) violates a provision of this chapter, the individual is:
 - (A) guilty of an infraction; and
 - (B) subject to a \$100 fine; or
 - (ii) intentionally or knowingly violates a provision of this chapter or violates this chapter three or more times, the individual is:
 - (A) guilty of a class B misdemeanor; and
 - (B) subject to a \$1,000 fine.
- (b) An individual who is guilty of a violation described in Subsection (9)(a) is not guilty of a violation of Title 58, Chapter 37, Utah Controlled Substances Act, for the conduct underlying the violation described in Subsection (9)(a).

(10) Nothing in this section prohibits:

- (a) the department from referring potential criminal activity to law enforcement; or
- (b) the attorney general from investigating or prosecuting individuals or businesses for violations of Title 76, Chapter 10, Part 31, Utah Antitrust Act.

[~~(11) An appeal of administrative action taken under this chapter shall be heard by an administrative law judge as an informal proceeding in accordance with Title 63G, Chapter 4, Administrative Procedures Act.]~~

Section 11. Section **26B-4-201** is amended to read:

HB0389 compared with HB0389S01

1050 26B-4-201. Definitions.

As used in this part:

- 576 (1) "Active tetrahydrocannabinol" means THC, any THC analog, and tetrahydrocannabinolic acid.
- 578 (2) "Administration of criminal justice" means the performance of detection, apprehension, detention, pretrial release, post-trial release, prosecution, and adjudication.
- 580 (3) "Advertise" means information provided by a person in any medium:
 - 581 (a) to the public; and
 - 582 (b) that is not age restricted to an individual who is at least 21 years old.
- 583 (4) "Advisory board" means the Medical Cannabis Policy Advisory Board created in Section
584 [26B-1-435] 4-41a-111.
- 585 (5) "Cannabis" means marijuana.
- 586 (6) "Cannabis cultivation facility" means the same as that term is defined in Section 4-41a-102.
- 588 [6] (7) "Cannabis processing facility" means the same as that term is defined in Section 4-41a-102.
- 590 [7] (8) "Cannabis product" means a product that:
 - 591 (a) is intended for human use; and
 - 592 (b) contains cannabis or any tetrahydrocannabinol or THC analog in a total concentration of 0.3% or greater on a dry weight basis.
- 594 [8] (9) "Cannabis production establishment" means the same as that term is defined in Section 4-41a-102.
- 596 [9] (10) "Cannabis production establishment agent" means the same as that term is defined in Section 4-41a-102.
- 598 [10] (11) "Cannabis production establishment agent registration card" means the same as that term is defined in Section 4-41a-102.
- 600 [11] (12) "Conditional medical cannabis card" means an electronic medical cannabis card that the department issues in accordance with Subsection 26B-4-213(1)(b) to allow an applicant for a medical cannabis card to access medical cannabis during the department's review of the application.
- 604 [12] (13) "Controlled substance database" means the controlled substance database created in Section 58-37f-201.
- 606 [13] (14) "Delivery address" means the same as that term is defined in Section 4-41a-102.
- 607 [14] (15) "Department" means the Department of Health and Human Services Department of Agriculture and Food.

HB0389 compared with HB0389S01

608 [15] (16) "Designated caregiver" means:
609 (a) an individual:
610 (i) whom an individual with a medical cannabis patient card or a medical cannabis guardian card
611 designates as the patient's caregiver; and
612 (ii) who registers with the department under Section 26B-4-214; or
613 (b)
614 (i) a facility that an individual designates as a designated caregiver in accordance with Subsection
615 26B-4-214(1)(b); or
616 (ii) an assigned employee of the facility described in Subsection 26B-4-214(1)(b)(ii).
617 [16] (17) "Directions of use" means recommended routes of administration for a medical cannabis
618 treatment and suggested usage guidelines.
619 [17] (18) "Dosing guidelines" means a quantity range and frequency of administration for a
620 recommended treatment of medical cannabis.
621 [18] (19) "Government issued photo identification" means any of the following forms of
622 identification:
623 (a) a valid state-issued driver license or identification card;
624 (b) a valid United States federal-issued photo identification, including:
625 (i) a United States passport;
626 (ii) a United States passport card;
627 (iii) a United States military identification card; or
628 (iv) a permanent resident card or alien registration receipt card; or
629 (c) a foreign passport.
630 [19] (20) "Home delivery medical cannabis pharmacy" means a medical cannabis pharmacy that the
631 department authorizes, as part of the pharmacy's license, to deliver medical cannabis shipments to a
632 delivery address to fulfill electronic orders.
633 [20] (21) "Inventory control system" means the system described in Section 4-41a-103.
634 [21] (22) "Legal dosage limit" means an amount that:
635 (a) is sufficient to provide 30 days of treatment based on the dosing guidelines that the relevant
636 recommending medical provider or pharmacy medical provider, in accordance with Subsection
637 26B-4-231(5), recommends; and
638 (b) may not exceed:

HB0389 compared with HB0389S01

638 (i) for unprocessed cannabis in a medicinal dosage form, 113 grams by weight; and
639 (ii) for a cannabis product in a medicinal dosage form, a quantity that contains, in total, greater than 20
grams of active tetrahydrocannabinol.

641 [~~(22)~~] (23) "Legal use termination date" means a date on the label of a container of unprocessed
cannabis flower:

643 (a) that is 60 days after the date of purchase of the cannabis; and
644 (b) after which, the cannabis is no longer in a medicinal dosage form outside of the primary residence of
the relevant medical cannabis patient cardholder.

646 (24)

647 (a) "Low THC product" means a product that:

648 (i) is intended for human use;
648 (ii) contains cannabis or any tetrahydrocannabinol or THC analog in a total concentration of less
than 0.3% on a dry weight basis; and
650 (iii) is processed by a cannabis processing facility.

651 (b) "Low THC product" does not include a product registered under Chapter 41, Hemp and
Cannabinoid Act.

653 [~~(23)~~] (25) "Marijuana" means the same as that term is defined in Section 58-37-2.

654 [~~(24)~~] (26) "Medical cannabis" or "medical cannabis product" means

655 (a) [-]cannabis in a medicinal dosage form[-or] ;
656 (b) a cannabis product in a medicinal dosage form[-] ; or
657 (c) a low THC product in a medicinal dosage form.

658 [~~(25)~~] (27) "Medical cannabis card" means a medical cannabis patient card, a medical cannabis
guardian card, a medical cannabis caregiver card, or a conditional medical cannabis card.

661 [~~(26)~~] (28) "Medical cannabis cardholder" means:

662 (a) a holder of a medical cannabis card; or
663 (b) a facility or assigned employee, described in Subsection [~~(15)(b)~~] (16)(b), only:
664 (i) within the scope of the facility's or assigned employee's performance of the role of a medical
cannabis patient cardholder's caregiver designation under Subsection 26B-4-214(1)(b); and
667 (ii) while in possession of documentation that establishes:
668 (A) a caregiver designation described in Subsection 26B-4-214(1)(b);
669 (B) the identity of the individual presenting the documentation; and

HB0389 compared with HB0389S01

670 (C) the relation of the individual presenting the documentation to the caregiver designation.

672 [~~27~~] (29) "Medical cannabis caregiver card" means an electronic document that a cardholder may print or store on an electronic device or a physical card or document that:

674 (a) the department issues to an individual whom a medical cannabis patient cardholder or a medical cannabis guardian cardholder designates as a designated caregiver; and

676 (b) is connected to the electronic verification system.

677 [~~28~~] (30) "Medical cannabis courier" means the same as that term is defined in Section 4-41a-102.

679 [~~29~~] (31)

(a) "Medical cannabis device" means a device that an individual uses to ingest or inhale medical cannabis.

681 (b) "Medical cannabis device" does not include a device that:

682 (i) facilitates cannabis combustion; or

683 (ii) an individual uses to ingest substances other than cannabis.

684 [~~30~~] (32) "Medical cannabis guardian card" means an electronic document that a cardholder may print or store on an electronic device or a physical card or document that:

686 (a) the department issues to the parent or legal guardian of a minor with a qualifying condition; and

688 (b) is connected to the electronic verification system.

689 [~~31~~] (33) "Medical cannabis patient card" means an electronic document that a cardholder may print or store on an electronic device or a physical card or document that:

691 (a) the department issues to an individual with a qualifying condition; and

692 (b) is connected to the electronic verification system.

693 [~~32~~] (34) "Medical cannabis pharmacy" means a person that:

694 (a)

(i) acquires or intends to acquire medical cannabis from a cannabis processing facility or another medical cannabis pharmacy or a medical cannabis device; or

696 (ii) possesses medical cannabis or a medical cannabis device; and

697 (b) sells or intends to sell medical cannabis or a medical cannabis device to a medical cannabis cardholder.

699 [~~33~~] (35) "Medical cannabis pharmacy agent" means an individual who holds a valid medical cannabis pharmacy agent registration card issued by the department.

701

HB0389 compared with HB0389S01

[{34}] (36) "Medical cannabis pharmacy agent registration card" means a registration card issued by the department that authorizes an individual to act as a medical cannabis pharmacy agent.

704 [({35})] (37) "Medical cannabis shipment" means the same as that term is defined in Section 4-41a-102.

706 [({36})] (38) "Medical cannabis treatment" means medical cannabis or a medical cannabis device.

708 [({37})] (39)

(a) "Medicinal dosage form" means:

709 (i) for processed medical cannabis, the following with a specific and consistent cannabinoid content:

711 (A) a tablet;

712 (B) a capsule;

713 (C) a concentrated liquid or viscous oil;

714 (D) a liquid suspension that does not exceed 30 milliliters;

715 (E) a topical preparation;

716 (F) a transdermal preparation;

717 (G) a sublingual preparation;

718 (H) a gelatinous cube, gelatinous rectangular cuboid, or lozenge in a cube or rectangular cuboid shape;

720 (I) a resin or wax;

721 (J) an aerosol;

722 (K) a suppository preparation; or

723 (L) a soft or hard confection that is a uniform rectangular cuboid or uniform spherical shape, is homogeneous in color and texture, and each piece is a single serving; or

726 (ii) for unprocessed cannabis flower, a container described in Section 4-41a-602 that:

727 (A) contains cannabis flower in a quantity that varies by no more than 10% from the stated weight at the time of packaging;

729 (B) at any time the medical cannabis cardholder transports or possesses the container in public, is contained within an opaque bag or box that the medical cannabis pharmacy provides; and

732 (C) is labeled with the container's content and weight, the date of purchase, the legal use termination date, and a barcode that provides information connected to an inventory control system.

735 (b) "Medicinal dosage form" includes a portion of unprocessed cannabis flower that:

736 (i) the medical cannabis cardholder has recently removed from the container described in Subsection [({37})(a)(ii)] (39)(a)(ii) for use; and

HB0389 compared with HB0389S01

738 (ii) does not exceed the quantity described in Subsection [(37)(a)(ii)] (39)(a)(ii).

739 (c) "Medicinal dosage form" does not include:

740 (i) any unprocessed cannabis flower outside of the container described in Subsection [(37)(a)(ii)] (39)
741 (a)(ii), except as provided in Subsection [(37)(b)] (39)(b);

742 (ii) any unprocessed cannabis flower in a container described in Subsection [(37)(a)(ii)] (39)(a)(ii) after
743 the legal use termination date;

744 (iii) a process of vaporizing and inhaling concentrated cannabis by placing the cannabis on a nail or
745 other metal object that is heated by a flame, including a blowtorch;

747 (iv) a liquid suspension that is branded as a beverage;

748 (v) a substance described in Subsection [(37)(a)(i)] (39)(a)(i) or (ii) if the substance is not measured in
749 grams, milligrams, or milliliters; or

750 (vi) a substance that contains or is covered to any degree with chocolate.

751 [(38)] (40) "Nonresident patient" means an individual who:

752 (a) is not a resident of Utah or has been a resident of Utah for less than 45 days;

753 (b) has a currently valid medical cannabis card or the equivalent of a medical cannabis card under the
754 laws of another state, district, territory, commonwealth, or insular possession of the United States;
755 and

756 (c) has been diagnosed with a qualifying condition as described in Section 26B-4-203.

757 [(39)] (41) "Patient product information insert" means a single page document or webpage that contains
758 information about a medical cannabis product regarding:

759 (a) how to use the product;

760 (b) common side effects;

761 (c) serious side effects;

762 (d) dosage;

763 (e) contraindications;

764 (f) safe storage;

765 (g) information on when a product should not be used; and

766 (h) other information the department deems appropriate in consultation with the cannabis processing
767 facility that created the product.

768 [(40)] (42) "Pharmacy medical provider" means the medical provider required to be on site at a medical
769 cannabis pharmacy under Section 26B-4-219.

HB0389 compared with HB0389S01

770 [41] (43) "Provisional patient card" means a card that:

771 (a) the department issues to a minor with a qualifying condition for whom:

772 (i) a recommending medical provider has recommended a medical cannabis treatment; and

774 (ii) the department issues a medical cannabis guardian card to the minor's parent or legal guardian; and

776 (b) is connected to the electronic verification system.

777 [42] (44) "Qualified Patient Enterprise Fund" means the enterprise fund created in Section [26B-1-310] 4-41a-104.1.

779 [43] (45) "Qualifying condition" means a condition described in Section 26B-4-203.

780 [44] (46) "Recommend" or "recommendation" means, for a recommending medical provider, the act of suggesting the use of medical cannabis treatment, which:

782 (a) certifies the patient's eligibility for a medical cannabis card; and

783 (b) may include, at the recommending medical provider's discretion, directions of use, with or without dosing guidelines.

785 [45] (47) "Recommending medical provider" means an individual who:

786 (a) meets the recommending qualifications;

787 (b) completes four hours of continuing medical education specific to medical cannabis through formal or informal sources; and

789 (c) every two years, provides an acknowledgment to the department that the individual completed four hours of continuing medical education.

791 [46] (48) "Recommending qualifications" means that an individual:

792 (a)

793 (i) has the authority to write a prescription;

795 (ii) is licensed to prescribe a controlled substance under Title 58, Chapter 37, Utah Controlled Substances Act; and

797 (iii) possesses the authority, in accordance with the individual's scope of practice, to prescribe a Schedule II controlled substance; and

798 (b) is licensed as:

799 (i) a podiatrist under Title 58, Chapter 5a, Podiatric Physician Licensing Act;

801 (ii) an advanced practice registered nurse under Title 58, Chapter 31b, Nurse Practice Act;

801 (iii) a physician under Title 58, Chapter 67, Utah Medical Practice Act, or Title 58, Chapter 68, Utah Osteopathic Medical Practice Act; or

HB0389 compared with HB0389S01

803 (iv) a physician assistant under Title 58, Chapter 70a, Utah Physician Assistant Act.

804 [~~(47)~~] (49) "State electronic verification system" means the system described in Section 26B-4-202.

806 [~~(48)~~] (50) "Targeted marketing" means the promotion by a recommending medical provider, medical clinic, or medical office that employs a recommending medical provider of a medical cannabis recommendation service using any of the following methods:

810 (a) electronic communication to an individual who is at least 21 years old and has requested to receive promotional information;

812 (b) an in-person marketing event that is held in an area where only an individual who is at least 21 years old may access the event;

814 (c) other marketing material that is physically or digitally displayed in the office of the medical clinic or office that employs a recommending medical provider; or

816 (d) a leaflet that a recommending medical provider, medical clinic, or medical office that employs a recommending medical provider shares with an individual who is at least 21 years old.

819 [~~(49)~~] (51) "Tetrahydrocannabinol" or "THC" means a substance derived from cannabis or a synthetic equivalent as described in Subsection 58-37-4(2)(a)(iii)(AA).

821 [~~(50)~~] (52) "THC analog" means the same as that term is defined in Section 4-41-102.

1299 Section 12. Section **12** is enacted to read:

26B-4-201.1. Transition of duties.

1301 (1) As used in this section, "transition period" means the period of time beginning on May 6, 2026, and ending on January 1, 2027.

1303 (2) During the transition period:

1304 (a) the department may request:

1305 (i) the Department of Health and Human Services to carry out the duties described in this part; or

1307 (ii) technical assistance from the Department of Health and Human Services related to carrying out the duties described in this part;

1309 (b) the department may terminate or limit the scope of the Department of Health and Human Services's power to carry out duties described in this part; or

1311 (c) if the department requests the Department of Health and Human Services to carry out duties described in this part, the department may make personnel available to the Department of Health and Human Services for carrying out the duties.

HB0389 compared with HB0389S01

(3) Upon the request of the department under this section, the Department of Health and Human Services has the authority to carry out any duties:

(a) within the scope of the request; and

(b) if related to this part.

(4) Notwithstanding any other provision of law, the Department of Health and Human Services may use funds from the Qualified Patient Enterprise Fund to cover any costs incurred by the Department of Health and Human Services related to carrying out duties requested by the department under this section.

Section 13. Section 26B-4-202 is amended to read:

26B-4-202. Electronic verification system.

(1) The [Department of Agriculture and Food, the]department, the Department of Public Safety, and the Division of Technology Services shall:

(a) enter into a memorandum of understanding in order to determine the function and operation of the state electronic verification system in accordance with Subsection (2);

(b) coordinate with the Division of Purchasing, under Title 63G, Chapter 6a, Utah Procurement Code, to develop a request for proposals for a third-party provider to develop and maintain the state electronic verification system in coordination with the Division of Technology Services; and

(c) select a third-party provider who:

(i) meets the requirements contained in the request for proposals issued under Subsection (1)(b); and

(ii) may not have any commercial or ownership interest in a cannabis production establishment or a medical cannabis pharmacy.

(2) The [Department of Agriculture and Food, the]department, the Department of Public Safety, and the Division of Technology Services shall ensure that the state electronic verification system described in Subsection (1):

(a) allows an individual to apply for a medical cannabis patient card or, if applicable, a medical cannabis guardian card, provided that the card may not become active until:

(i) the relevant recommending medical provider completes the associated medical cannabis recommendation; or

(ii) the medical cannabis pharmacy completes the recording described in Subsection (2)(d);

(b) allows an individual to apply to renew a medical cannabis patient card or a medical cannabis guardian card in accordance with Section 26B-4-213;

HB0389 compared with HB0389S01

1348 (c) allows a recommending medical provider, or an employee described in Subsection (3) acting on
behalf of the recommending medical provider, to:

1350 (i) access dispensing and card status information regarding a patient:
1351 (A) with whom the recommending medical provider has a provider-patient relationship; and
1353 (B) for whom the recommending medical provider has recommended or is considering recommending a
medical cannabis card;

1355 (ii) electronically recommend treatment with medical cannabis and optionally recommend dosing
guidelines;

1357 (iii) electronically renew a recommendation to a medical cannabis patient cardholder or medical
cannabis guardian cardholder:
1359 (A) using telehealth services, for the recommending medical provider who originally recommended a
medical cannabis treatment during a face-to-face visit with the patient; or
1362 (B) during a face-to-face visit with the patient, for a recommending medical provider who did not
originally recommend the medical cannabis treatment during a face-to-face visit; and
1365 (iv) submit an initial application, renewal application, or application payment on behalf of an individual
applying for any of the following:
1367 (A) a medical cannabis patient card;
1368 (B) a medical cannabis guardian card; or
1369 (C) a medical cannabis caregiver card;

1370 (d) allows a medical cannabis pharmacy medical provider or medical cannabis pharmacy agent, in
accordance with Subsection 4-41a-1101(10)(a), to:

1372 (i) access the electronic verification system to review the history within the system of a patient
with whom the provider or agent is interacting, limited to read-only access for medical cannabis
pharmacy agents unless the medical cannabis pharmacy's pharmacist in charge authorizes add and
edit access;

1376 (ii) record a patient's recommendation from a recommending medical provider, including any directions
of use, dosing guidelines, or caregiver indications from the recommending medical provider;

1379 (iii) record a recommending medical provider's renewal of the provider's previous recommendation; and
1381 (iv) submit an initial application, renewal application, or application payment on behalf of an individual
applying for any of the following:
1383 (A) a medical cannabis patient card;

HB0389 compared with HB0389S01

1384 (B) a medical cannabis guardian card; or

1385 (C) a medical cannabis caregiver card;

1386 (e) connects with:

1387 (i) an inventory control system that a medical cannabis pharmacy uses to track in real time and archive
purchases of any medical cannabis or a medical cannabis device, including:

1390 (A) the time and date of each purchase;

1391 (B) the quantity and type of medical cannabis or medical cannabis device purchased;

1393 (C) any cannabis production establishment, any medical cannabis pharmacy, or any medical cannabis
courier associated with the medical cannabis or medical cannabis device; and

1396 (D) the personally identifiable information of the medical cannabis cardholder who made the purchase;
and

1398 (ii) any commercially available inventory control system that a cannabis production establishment
utilizes in accordance with Section 4-41a-103 to use data that the ~~Department of Agriculture and
Food~~ department requires by rule, in accordance with Title 63G, Chapter 3, Utah Administrative
Rulemaking Act, from the inventory tracking system that a licensee uses to track and confirm
compliance;

1403 (f) provides access to:

1404 (i) the department to the extent necessary to carry out the department's functions and responsibilities
under this part;

1406 (ii) the ~~Department of Agriculture and Food~~ department to the extent necessary to carry out the
functions and responsibilities of the ~~Department of Agriculture and Food~~ department under Title 4,
Chapter 41a, Cannabis Production Establishments and Pharmacies; and

1410 (iii) the Division of Professional Licensing to the extent necessary to carry out the functions and
responsibilities related to the participation of the following in the recommendation and dispensing of
medical cannabis:

1413 (A) a podiatrist licensed under Title 58, Chapter 5a, Podiatric Physician Licensing Act;

1415 (B) a pharmacist licensed under Title 58, Chapter 17b, Pharmacy Practice Act;

1416 (C) an advanced practice registered nurse licensed under Title 58, Chapter 31b, Nurse Practice Act;

1418 (D) a physician licensed under Title 58, Chapter 67, Utah Medical Practice Act, or Title 58, Chapter 68,
Utah Osteopathic Medical Practice Act; or

1420 (E) a physician assistant licensed under Title 58, Chapter 70a, Utah Physician Assistant Act;

HB0389 compared with HB0389S01

1422 (g) communicates dispensing information from a record that a medical cannabis pharmacy submits to the state electronic verification system under Subsection 4-41a-1102(3)(a)(ii) to the controlled substance database;

1425 (h) provides access to state or local law enforcement only to verify the validity of an individual's medical cannabis card for the administration of criminal justice and through a database used by law enforcement; and

1428 (i) creates a record each time a person accesses the system that identifies the person who accesses the system and the individual whose records the person accesses.

1430 (3)

1433 (a) An employee of a recommending medical provider may access the electronic verification system for a purpose described in Subsection (2)(c) on behalf of the recommending medical provider if:

1436 (i) the recommending medical provider has designated the employee as an individual authorized to access the electronic verification system on behalf of the recommending medical provider;

1438 (ii) the recommending medical provider provides written notice to the department of the employee's identity and the designation described in Subsection (3)(a)(i); and

1440 (iii) the department grants to the employee access to the electronic verification system.

1443 (b) An employee of a business that employs a recommending medical provider may access the electronic verification system for a purpose described in Subsection (2)(c) on behalf of the recommending medical provider if:

1446 (i) the recommending medical provider has designated the employee as an individual authorized to access the electronic verification system on behalf of the recommending medical provider;

1449 (ii) the recommending medical provider and the employing business jointly provide written notice to the department of the employee's identity and the designation described in Subsection (3)(b)(i); and

1451 (iii) the department grants to the employee access to the electronic verification system.

1456 (4)

1457 (a) As used in this Subsection (4), "prescribing provider" means:

(i) a podiatrist licensed under Title 58, Chapter 5a, Podiatric Physician Licensing Act;

HB0389 compared with HB0389S01

1458 (ii) an advanced practice registered nurse licensed under Title 58, Chapter 31b, Nurse Practice Act;

1460 (iii) a physician licensed under Title 58, Chapter 67, Utah Medical Practice Act, or Title 58,

1462 Chapter 68, Utah Osteopathic Medical Practice Act; or

1464 (iv) a physician assistant licensed under Title 58, Chapter 70a, Utah Physician Assistant Act.

1466 (b) A prescribing provider may access information in the electronic verification system regarding a patient the prescribing provider treats.

1467 (5) The department may release limited data that the system collects for the purpose of:

1468 (a) conducting medical and other department approved research;

1469 (b) providing the report required by Section 26B-4-222; and

1470 (c) other official department purposes.

1472 (6) The department shall make rules, in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, to establish:

1474 (a) the limitations on access to the data in the state electronic verification system as described in this section; and

1476 (b) standards and procedures to ensure accurate identification of an individual requesting information or receiving information in this section.

1479 (7) Any person who negligently or recklessly releases any information in the state electronic verification system in violation of this section is guilty of a class C misdemeanor.

1481 (8) Any person who obtains or attempts to obtain information from the state electronic verification system by misrepresentation or fraud is guilty of a third degree felony.

1482 (9)

1483 (a) Except as provided in Subsections (9)(c) and (9)(e), a person may not knowingly and intentionally use, release, publish, or otherwise make available to any other person information obtained from the state electronic verification system for any purpose other than a purpose specified in this section.

1485 (b) Each separate violation of this Subsection (9) is:

1486 (i) a third degree felony; and

1487 (ii) subject to a civil penalty not to exceed \$5,000.

1488 (c) A law enforcement officer who uses the database used by law enforcement to access information in the electronic verification system for a reason that is not the administration of criminal justice is guilty of a class B misdemeanor.

HB0389 compared with HB0389S01

- (d) The department shall determine a civil violation of this Subsection (9) in accordance with Title 63G, Chapter 4, Administrative Procedures Act.
- (e) Civil penalties assessed under this Subsection (9) shall be deposited into the General Fund.
- (f) This Subsection (9) does not prohibit a person who obtains information from the state electronic verification system under Subsection (2)(a), (c), or (f) from:
 - (i) including the information in the person's medical chart or file for access by a person authorized to review the medical chart or file;
 - (ii) providing the information to a person in accordance with the requirements of the Health Insurance Portability and Accountability Act of 1996; or
 - (iii) discussing or sharing that information about the patient with the patient.

Section 14. Section **26B-4-213** is amended to read:

26B-4-213. Medical cannabis patient card -- Medical cannabis guardian card -- Conditional medical cannabis card -- Application -- Fees -- Studies.

- (1) (a) Subject to Section 26B-4-246, within 15 days after the day on which an individual who satisfies the eligibility criteria in this section or Section 26B-4-214 submits an application in accordance with this section or Section 26B-4-214, the department shall:
 - (i) issue a medical cannabis patient card to an individual described in Subsection (2)(a);
 - (ii) issue a medical cannabis guardian card to an individual described in Subsection (2)(b);
 - (iii) issue a provisional patient card to a minor described in Subsection (2)(c); and
 - (iv) issue a medical cannabis caregiver card to an individual described in Subsection 26B-4-214(4).
- (b) (i) Upon the entry of a recommending medical provider's medical cannabis recommendation for a patient in the state electronic verification system, either by the provider or the provider's employee or by a medical cannabis pharmacy medical provider or medical cannabis pharmacy in accordance with Subsection 4-41a-1101(10)(a), the department shall issue to the patient an electronic conditional medical cannabis card, in accordance with this Subsection (1)(b).
 - (ii) A conditional medical cannabis card is valid for the lesser of:
 - (A) 60 days; or

HB0389 compared with HB0389S01

(B) the day on which the department completes the department's review and issues a medical cannabis card under Subsection (1)(a), denies the patient's medical cannabis card application, or revokes the conditional medical cannabis card under Subsection (8).

848 (iii) The department may issue a conditional medical cannabis card to an individual applying for a medical cannabis patient card for which approval of the Compassionate Use Board is not required.

851 (iv) An individual described in Subsection (1)(b)(iii) has the rights, restrictions, and obligations under law applicable to a holder of the medical cannabis card for which the individual applies and for which the department issues the conditional medical cannabis card.

855 (2)

(a) An individual is eligible for a medical cannabis patient card if:

856 (i)

(A) the individual is at least 21 years old; or

857 (B) the individual is 18, 19, or 20 years old, the individual petitions the Compassionate Use Board under Section 26B-1-421, and the Compassionate Use Board recommends department approval of the petition;

860 (ii) the individual is a Utah resident;

861 (iii) the individual's recommending medical provider recommends treatment with medical cannabis in accordance with Subsection (4);

863 (iv) the individual signs an acknowledgment stating that the individual received the information described in Subsection (9); and

865 (v) the individual pays to the department a fee in an amount that, subject to Subsection [26B-1-310(5)] 4-41a-104.1(5), the department sets in accordance with Section 63J-1-504.

868 (b)

(i) An individual is eligible for a medical cannabis guardian card if the individual:

869 (A) is at least 18 years old;

870 (B) is a Utah resident;

871 (C) is the parent or legal guardian of a minor for whom the minor's recommending medical provider recommends a medical cannabis treatment, the individual petitions the Compassionate Use Board under Section 26B-1-421, and the Compassionate Use Board recommends department approval of the petition;

HB0389 compared with HB0389S01

(D) the individual signs an acknowledgment stating that the individual received the information described in Subsection (9); and

877 (E) pays to the department a fee in an amount that, subject to Subsection [26B-1-310(5)] 4-41a-104.1(5), the department sets in accordance with Section 63J-1-504, plus the cost of the criminal background check described in Section 26B-4-215.

881 (ii) The department shall notify the Department of Public Safety of each individual that the department registers for a medical cannabis guardian card.

883 (c)

884 (i) A minor is eligible for a provisional patient card if:

885 (A) the minor has a qualifying condition;

887 (B) the minor's recommending medical provider recommends a medical cannabis treatment to address the minor's qualifying condition;

890 (C) one of the minor's parents or legal guardians petitions the Compassionate Use Board under Section 26B-1-421, and the Compassionate Use Board recommends department approval of the petition; and

893 (D) the minor's parent or legal guardian is eligible for a medical cannabis guardian card under Subsection (2)(b) or designates a caregiver under Subsection (2)(d) who is eligible for a medical cannabis caregiver card under Section 26B-4-214.

896 (ii) The department shall automatically issue a provisional patient card to the minor described in Subsection (2)(c)(i) at the same time the department issues a medical cannabis guardian card to the minor's parent or legal guardian.

901 (d) If the parent or legal guardian of a minor described in Subsections (2)(c)(i)(A) through (C) does not qualify for a medical cannabis guardian card under Subsection (2)(b), the parent or legal guardian may designate up to two caregivers in accordance with Subsection 26B-4-214(1)(c) to ensure that the minor has adequate and safe access to the recommended medical cannabis treatment.

903 (3)

905 (a) An individual who is eligible for a medical cannabis card described in Subsection (2)(a) or (b) shall submit an application for a medical cannabis card to the department:

906 (i) through an electronic application connected to the state electronic verification system;

(ii) with the recommending medical provider; and

(iii) with information including:

HB0389 compared with HB0389S01

- 907 (A) the applicant's name, gender, age, and address;
- 908 (B) the number of the applicant's government issued photo identification;
- 909 (C) for a medical cannabis guardian card, the name, gender, and age of the minor receiving a medical
cannabis treatment under the cardholder's medical cannabis guardian card; and
- 912 (D) for a provisional patient card, the name of the minor's parent or legal guardian who holds the
associated medical cannabis guardian card.

914 (b)

- (i) If a recommending medical provider determines that, because of age, illness, or disability, a medical cannabis patient cardholder requires assistance in administering the medical cannabis treatment that the recommending medical provider recommends, the recommending medical provider may indicate the cardholder's need in the state electronic verification system, either directly or through the order described in Subsections 26B-4-204(1)(b) and (c).
- (ii) If a recommending medical provider makes the indication described in Subsection (3)(b)(i):
 - (A) the department shall add a label to the relevant medical cannabis patient card indicating the cardholder's need for assistance;
 - (B) any adult who is 18 years old or older and who is physically present with the cardholder at the time the cardholder needs to use the recommended medical cannabis treatment may handle the medical cannabis treatment and any associated medical cannabis device as needed to assist the cardholder in administering the recommended medical cannabis treatment; and
 - (C) an individual of any age who is physically present with the cardholder in the event of an emergency medical condition, as that term is defined in Section 31A-1-301, may handle the medical cannabis treatment and any associated medical cannabis device as needed to assist the cardholder in administering the recommended medical cannabis treatment.
- (iii) A non-cardholding individual acting under Subsection (3)(b)(ii)(B) or (C) may not:
 - (A) ingest or inhale medical cannabis;
 - (B) possess, transport, or handle medical cannabis or a medical cannabis device outside of the immediate area where the cardholder is present or with an intent other than to provide assistance to the cardholder; or
 - (C) possess, transport, or handle medical cannabis or a medical cannabis device when the cardholder is not in the process of being dosed with medical cannabis.

942 (4)

HB0389 compared with HB0389S01

(a) [Except as provided in Subsection (4)(b), a-] A recommending medical provider may [not] recommend medical cannabis to a patient through a virtual visit.

944 (b) ~~A~~ recommending medical provider may recommend medical cannabis to a patient through a virtual visit if the patient:]

946 (i) ~~is on hospice or has a terminal illness according to the patient's medical provider;~~]

947 (ii) ~~is a resident of an assisted living facility, as defined in Section 26B-2-201, or a nursing care facility, as defined in Section 26B-2-201;~~]

949 (iii) ~~has previously received a medical cannabis recommendation from the recommending medical provider through a face-to-face visit; or~~]

951 (iv) ~~is a current patient of the recommending medical provider and has met with the recommending medical provider face-to-face previously.]~~

953 [(e)] (b) A recommending medical provider shall:

954 (i) before recommending or renewing a recommendation for medical cannabis in a medicinal dosage form or a cannabis product in a medicinal dosage form:

956 (A) verify the patient's and, for a minor patient, the minor patient's parent or legal guardian's government issued photo identification described in Subsection (3)(a);

959 (B) review any record related to the patient and, for a minor patient, the patient's parent or legal guardian accessible to the recommending medical provider including in the controlled substance database created in Section 58-37f-201; and

963 (C) consider the recommendation in light of the patient's qualifying condition, history of substance use or opioid use disorder, and history of medical cannabis and controlled substance use during a visit with the patient; and

966 (ii) state in the recommending medical provider's recommendation that the patient:

967 (A) suffers from a qualifying condition, including the type of qualifying condition; and

969 (B) may benefit from treatment with cannabis in a medicinal dosage form or a cannabis product in a medicinal dosage form.

971 (5)

973 (a) Except as provided in Subsection (5)(b) or (c), a medical cannabis card that the department issues under this section is valid for the lesser of:

974 (i) an amount of time that the recommending medical provider determines; or

974 (ii) one year from the day the card is issued.

HB0389 compared with HB0389S01

975 (b)

- (i) A medical cannabis card that the department issues in relation to a terminal illness described in Section 26B-4-203 expires after one year.

977 (ii) The recommending medical provider may revoke a recommendation that the provider made in relation to a terminal illness described in Section 26B-4-203 if the medical cannabis cardholder no longer has the terminal illness.

980 (c) A medical cannabis card that the department issues in relation to acute pain as described in Section 26B-4-203 expires 30 days after the day on which the department first issues a conditional or full medical cannabis card.

983 (6)

- (a) A medical cannabis patient card or a medical cannabis guardian card is renewable if:
 - (i) at the time of renewal, the cardholder meets the requirements of Subsection (2)(a) or (b); or
 - (ii) the cardholder received the medical cannabis card through the recommendation of the Compassionate Use Board under Section 26B-1-421.

989 (b) The recommending medical provider who made the underlying recommendation for the card of a cardholder described in Subsection (6)(a) may renew the cardholder's card through phone or video conference with the cardholder, at the recommending medical provider's discretion.

993 (c) Before having access to a renewed card, a cardholder under Subsection (2)(a) or (b) shall pay to the department a renewal fee in an amount that:

- (i) subject to Subsection [26B-1-310(5)] 4-41a-104.1(5), the department sets in accordance with Section 63J-1-504; and
- (ii) may not exceed the cost of the relatively lower administrative burden of renewal in comparison to the original application process.

999 (d) If a minor meets the requirements of Subsection (2)(c), the minor's provisional patient card renews automatically at the time the minor's parent or legal guardian renews the parent or legal guardian's associated medical cannabis guardian card.

1002 (7)

- (a) A cardholder under this section shall carry the cardholder's valid medical cannabis card with the patient's name.

1004 (b)

HB0389 compared with HB0389S01

- (i) A medical cannabis patient cardholder or a provisional patient cardholder may purchase, in accordance with this part and the recommendation underlying the card, cannabis in a medicinal dosage form, a cannabis product in a medicinal dosage form, or a medical cannabis device.
- 1008 (ii) A cardholder under this section may possess or transport, in accordance with this part and the recommendation underlying the card, cannabis in a medicinal dosage form, a cannabis product in a medicinal dosage form, or a medical cannabis device.
- 1012 (iii) To address the qualifying condition underlying the medical cannabis treatment recommendation:
 - 1014 (A) a medical cannabis patient cardholder or a provisional patient cardholder may use medical cannabis or a medical cannabis device; and
 - 1016 (B) a medical cannabis guardian cardholder may assist the associated provisional patient cardholder with the use of medical cannabis or a medical cannabis device.
- 1019 (8)
 - (a) The department may revoke a medical cannabis card that the department issues under this section if:
 - 1021 (i) the recommending medical provider withdraws the medical provider's recommendation for medical cannabis; or
 - 1023 (ii) the cardholder:
 - 1024 (A) violates this part; or
 - 1025 (B) is convicted under state or federal law of, after March 17, 2021, a drug distribution offense.
 - 1027 (b) The department may not refuse to issue a medical cannabis card to a patient solely based on a prior revocation under Subsection (8)(a)(i).
- 1029 (9) The department shall establish by rule, in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, a process to provide information regarding the following to an individual receiving a medical cannabis card:
 - 1032 (a) risks associated with medical cannabis treatment;
 - 1033 (b) the fact that a condition's listing as a qualifying condition does not suggest that medical cannabis treatment is an effective treatment or cure for that condition, as described in Subsection 26B-4-203(1); and
 - 1036 (c) other relevant warnings and safety information that the department determines.
- 1037 (10) The department may establish procedures by rule, in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, to implement the application and issuance provisions of this section.

HB0389 compared with HB0389S01

1040 (11)

(a) The department shall establish by rule, in accordance with Title 63G, Chapter 3, Utah
Administrative Rulemaking Act, a process to allow an individual from another state to register with
the department in order to purchase medical cannabis or a medical cannabis device from a medical
cannabis pharmacy while the individual is visiting the state.

1045 (b) The department may only provide the registration process described in Subsection (11)(a):

1047 (i) to a nonresident patient; and

1048 (ii) for no more than two visitation periods per calendar year of up to 21 calendar days per visitation
period.

1050 (12)

(a) A person may submit to the department a request to conduct a research study using medical cannabis
cardholder data that the state electronic verification system contains.

1053 (b) The department shall review a request described in Subsection (12)(a) to determine whether an
institutional review board, as that term is defined in Section 26B-4-201, could approve the research
study.

1056 (c) At the time an individual applies for a medical cannabis card, the department shall notify the
individual:

1058 (i) of how the individual's information will be used as a cardholder;

1059 (ii) that by applying for a medical cannabis card, unless the individual withdraws consent under
Subsection (12)(d), the individual consents to the use of the individual's information for external
research; and

1062 (iii) that the individual may withdraw consent for the use of the individual's information for external
research at any time, including at the time of application.

1064 (d) An applicant may, through the medical cannabis card application, and a medical cannabis
cardholder may, through the state central patient portal, withdraw the applicant's or cardholder's
consent to participate in external research at any time.

1067 (e) The department may release, for the purposes of a study described in this Subsection (12),
information about a cardholder under this section who consents to participate under Subsection (12)
(c).

1070 (f) If an individual withdraws consent under Subsection (12)(d), the withdrawal of consent:
1072 (i) applies to external research that is initiated after the withdrawal of consent; and

HB0389 compared with HB0389S01

1073 (ii) does not apply to research that was initiated before the withdrawal of consent.

1074 (g) The department may establish standards for a medical research study's validity, by rule made in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act.

1077 (13) The department shall record the issuance or revocation of a medical cannabis card under this section in the controlled substance database.

1759 Section 15. Section **26B-4-214** is amended to read:

1760 **26B-4-214. Medical cannabis caregiver card -- Registration -- Renewal -- Revocation.**

1082 (1)

1085 (a) A cardholder described in Section 26B-4-213 may designate up to two individuals, or an individual and a facility in accordance with Subsection (1)(b), to serve as a designated caregiver for the cardholder.

(b)

(i) A cardholder described in Section 26B-4-213 may designate one of the following types of facilities as one of the caregivers described in Subsection (1)(a):

(A) for a patient or resident, an assisted living facility, as that term is defined in Section 26B-2-201;

(B) for a patient or resident, a nursing care facility, as that term is defined in Section 26B-2-201; or

(C) for a patient, a general acute hospital, as that term is defined in Section 26B-2-201.

(ii) A facility may:

(A) assign one or more employees to assist patients with medical cannabis treatment under the caregiver designation described in this Subsection (1)(b); and

(B) receive a medical cannabis shipment from a medical cannabis pharmacy or a medical cannabis courier on behalf of the medical cannabis cardholder within the facility who designated the facility as a caregiver.

(iii) The department shall make rules to regulate the practice of facilities and facility employees serving as designated caregivers under this Subsection (1)(b).

(c) A parent or legal guardian described in Subsection 26B-4-213(2)(d), in consultation with the minor and the minor's recommending medical provider, may designate up to two individuals to serve as a designated caregiver for the minor, if the department determines that the parent or legal guardian is not eligible for a medical cannabis guardian card under Section 26B-4-213.

(d)

HB0389 compared with HB0389S01

- (i) Upon the entry of a caregiver designation under Subsection (1)(c) by a patient with a terminal illness described in Section 26B-4-203, the department shall issue to the designated caregiver an electronic conditional medical cannabis caregiver card, in accordance with this Subsection (1)(d).
 - 1111 (ii) A conditional medical cannabis caregiver card is valid for the lesser of:
 - 1112 (A) 60 days; or
 - 1113 (B) the day on which the department completes the department's review and issues a medical cannabis caregiver card under Subsection (1)(a), denies the patient's medical cannabis caregiver card application, or revokes the conditional medical cannabis caregiver card under Section 26B-4-246.
 - 1117 (iii) The department may issue a conditional medical cannabis card to an individual applying for a medical cannabis patient card for which approval of the Compassionate Use Board is not required.
 - 1120 (iv) An individual described in Subsection (1)(b)(iii) has the rights, restrictions, and obligations under law applicable to a holder of the medical cannabis card for which the individual applies and for which the department issues the conditional medical cannabis card.
- 1124 (2) An individual that the department registers as a designated caregiver under this section and a facility described in Subsection (1)(b):
 - 1126 (a) for an individual designated caregiver, may carry a valid medical cannabis caregiver card;
 - 1128 (b) in accordance with this part, may purchase, possess, transport, or assist the patient in the use of medical cannabis or a medical cannabis device on behalf of the designating medical cannabis cardholder;
 - 1131 (c) may not charge a fee to an individual to act as the individual's designated caregiver or for a service that the designated caregiver provides in relation to the role as a designated caregiver; and
 - 1134 (d) may accept reimbursement from the designating medical cannabis cardholder for direct costs the designated caregiver incurs for assisting with the designating cardholder's medicinal use of cannabis.
- 1137 (3)
 - 1138 (a) The department shall:
 - 1138 (i) within 15 days after the day on which an individual submits an application in compliance with this section, issue a medical cannabis card to the applicant if the applicant:
 - 1141 (A) is designated as a caregiver under Subsection (1);
 - 1142 (B) is eligible for a medical cannabis caregiver card under Subsection (4); and
 - 1143 (C) complies with this section; and

HB0389 compared with HB0389S01

1144 (ii) notify the Department of Public Safety of each individual that the department registers as a
designated caregiver.

1146 (b) The department shall ensure that a medical cannabis caregiver card contains the information
described in Subsections (5)(b) and (3)(c)(i).

1148 (c) If a cardholder described in Section 26B-4-213 designates an individual as a caregiver who already
holds a medical cannabis caregiver card, the individual with the medical cannabis caregiver card:

1151 (i) shall report to the department the information required of applicants under Subsection (5)(b)
regarding the new designation;

1153 (ii) if the individual makes the report described in Subsection (3)(c)(i), is not required to file an
application for another medical cannabis caregiver card;

1155 (iii) may receive an additional medical cannabis caregiver card in relation to each additional medical
cannabis patient who designates the caregiver; and

1157 (iv) is not subject to an additional background check.

1158 (4) An individual is eligible for a medical cannabis caregiver card if the individual:

1159 (a) is at least 21 years old;

1160 (b) is a Utah resident;

1161 (c) pays to the department a fee in an amount that, subject to Subsection
[26B-1-310(5)] 4-41a-104.1(5), the department sets in accordance with Section 63J-1-504, plus the
cost of the criminal background check described in Section 26B-4-215; and

1164 (d) signs an acknowledgment stating that the applicant received the information described in Subsection
26B-4-213(9).

1166 (5) An eligible applicant for a medical cannabis caregiver card shall:

1167 (a) submit an application for a medical cannabis caregiver card to the department through an electronic
application connected to the state electronic verification system; and

1170 (b) submit the following information in the application described in Subsection (5)(a):

1171 (i) the applicant's name, gender, age, and address;

1172 (ii) the name, gender, age, and address of the cardholder described in Section 26B-4-213 who
designated the applicant;

1174 (iii) if a medical cannabis guardian cardholder designated the caregiver, the name, gender, and age
of the minor receiving a medical cannabis treatment in relation to the medical cannabis guardian
cardholder; and

HB0389 compared with HB0389S01

1177 (iv) any additional information that the department requests to assist in matching the application with
the designating medical cannabis patient.

1179 (6) Except as provided in Subsection (6)(b), a medical cannabis caregiver card that the department
issues under this section is valid for the lesser of:

1181 (a) an amount of time that the cardholder described in Section 26B-4-213 who designated the caregiver
determines; or

1183 (b) the amount of time remaining before the card of the cardholder described in Section 26B-4-213
expires.

1185 (7)

1188 (a) If a designated caregiver meets the requirements of Subsection (4), the designated caregiver's
medical cannabis caregiver card renews automatically at the time the cardholder described in
Section 26B-4-213 who designated the caregiver:

1189 (i) renews the cardholder's card; and

1190 (ii) renews the caregiver's designation, in accordance with Subsection (7)(b).

1192 (b) The department shall provide a method in the card renewal process to allow a cardholder described
in Section 26B-4-213 who has designated a caregiver to:

1193 (i) signify that the cardholder renews the caregiver's designation;

1194 (ii) remove a caregiver's designation; or

1195 (iii) designate a new caregiver.

1877 (8) The department shall record the issuance or revocation of a medical cannabis card under this section
in the controlled substance database.

1878 Section 16. Section **26B-4-219** is amended to read:

1879 **26B-4-219. Pharmacy medical providers -- Registration -- Continuing education.**

1199 (1)

1200 (a) A medical cannabis pharmacy:

1202 (i) shall employ a pharmacist who is licensed under Title 58, Chapter 17b, Pharmacy Practice Act,
as a pharmacy medical provider;

1206 (ii) may employ a physician who has the authority to write a prescription and is licensed under Title
58, Chapter 67, Utah Medical Practice Act, or Title 58, Chapter 68, Utah Osteopathic Medical
Practice Act, as a pharmacy medical provider;

HB0389 compared with HB0389S01

- (iii) shall ensure that a pharmacy medical provider described in Subsection (1)(a)(i) works onsite during all business hours; and
- (iv) shall designate one pharmacy medical provider described in Subsection (1)(a)(i) as the pharmacist-in-charge to oversee the operation of and generally supervise the medical cannabis pharmacy.

1208 (b) The pharmacist-in-charge shall determine which cannabis and cannabis products the medical cannabis pharmacy maintains in the medical cannabis pharmacy's inventory.

1211 (c) An individual may not serve as a pharmacy medical provider unless the department registers the individual as a pharmacy medical provider in accordance with Subsection (2).

1213 (2)

1216 (a) The department shall, within 15 days after the day on which the department receives an application from a medical cannabis pharmacy on behalf of a prospective pharmacy medical provider, register and issue a pharmacy medical provider registration card to the prospective pharmacy medical provider if the medical cannabis pharmacy:

- (i) provides to the department:
 - (A) the prospective pharmacy medical provider's name and address;
 - (B) the name and location of the licensed medical cannabis pharmacy where the prospective pharmacy medical provider seeks to act as a pharmacy medical provider;
 - (C) an acknowledgment that the individual has completed four hours of continuing education related to medical cannabis; and
 - (D) evidence that the prospective pharmacy medical provider is a pharmacist who is licensed under Title 58, Chapter 17b, Pharmacy Practice Act, or a physician who has the authority to write a prescription and is licensed under Title 58, Chapter 67, Utah Medical Practice Act, or Title 58, Chapter 68, Utah Osteopathic Medical Practice Act; and
- (ii) pays a fee to the department in an amount that, subject to Subsection [26B-1-310(5)] 4-41a-104.1(5), the department sets in accordance with Section 63J-1-504.

1221 (b) The department may not register a recommending medical provider as a pharmacy medical provider.

1222 (3)

1223 (a) A pharmacy medical provider shall complete the continuing education described in this Subsection (3) in the following amounts:

1226 (i) as a condition precedent to registration, four hours; and

1228 (ii) as a condition precedent to registration, four hours; and

1233 (iii) as a condition precedent to registration, four hours; and

1236 (iv) as a condition precedent to registration, four hours; and

1238 (v) as a condition precedent to registration, four hours; and

1240 (vi) as a condition precedent to registration, four hours; and

HB0389 compared with HB0389S01

1241 (ii) as a condition precedent to renewal of the registration, four hours every two years.

1242 (b) The department may, in consultation with the Division of Professional Licensing, develop the continuing education described in this Subsection (3).

1244 (c) The continuing education described in this Subsection (3) may discuss:

1245 (i) the provisions of this part;

1246 (ii) general information about medical cannabis under federal and state law;

1247 (iii) the latest scientific research on the endocannabinoid system and medical cannabis, including risks and benefits;

1249 (iv) recommendations for medical cannabis as it relates to the continuing care of a patient in pain management, risk management, potential addiction, and palliative care; or

1252 (v) best practices for recommending the form and dosage of medical cannabis based on the qualifying condition underlying a medical cannabis recommendation.

1254 (4)

1256 (a) A pharmacy medical provider registration card expires two years after the day on which the department issues or renews the card.

1258 (b) A pharmacy medical provider may renew the provider's registration card if the provider:

1259 (i) is eligible for a pharmacy medical provider registration card under this section;

1261 (ii) certifies to the department in a renewal application that the information in Subsection (2)(a) is accurate or updates the information;

1263 (iii) submits a report detailing the completion of the continuing education requirement described in Subsection (3); and

1265 (iv) pays to the department a renewal fee in an amount that:

1266 (A) subject to Subsection [26B-1-310(5)] 4-41a-104.1(5), the department sets in accordance with Section 63J-1-504; and

1268 (B) may not exceed the cost of the relatively lower administrative burden of renewal in comparison to the original application process.

1268 (5)

1270 (a) Except as provided in Subsection (5)(b), a person may not advertise that the person or another person dispenses medical cannabis.

(b) Notwithstanding Subsection (5)(a) and Section 4-41a-109, a registered pharmacy medical provider may advertise the following:

HB0389 compared with HB0389S01

1272 (i) a green cross;

1273 (ii) that the person is registered as a pharmacy medical provider and dispenses medical cannabis; or

1275 (iii) a scientific study regarding medical cannabis use.

1276 (6)

1278 (a) The department may revoke a pharmacy medical provider's registration for a violation of this chapter.

1278 (b) The department may inspect patient records held by a medical cannabis pharmacy to ensure a pharmacy medical provider is practicing in accordance with this chapter and applicable rules.

1961 Section 17. Section **26B-4-222** is amended to read:

1962 **26B-4-222. Report.**

1283 (1) By the November interim meeting each year, the department shall report to the Health and Human Services Interim Committee on:

1285 (a) the number of applications and renewal applications filed for medical cannabis cards;

1286 (b) the number of qualifying patients and designated caregivers;

1287 (c) the nature of the debilitating medical conditions of the qualifying patients;

1288 (d) the age and county of residence of cardholders;

1289 (e) the number of medical cannabis cards revoked;

1290 (f) the number of practitioners providing recommendations for qualifying patients; and

1291 (g) the expenses and revenues of the Qualified Patient Enterprise Fund created in Section [26B-1-310] 4-41a-104.1.

1293 (2) The report shall include information provided by the Center for Medical Cannabis Research described in Section 53H-4-206.

1295 (3) The department may not include personally identifying information in the report described in this section.

1297 (4) The department shall report to the working group described in Section 36-12-8.2 as requested by the working group.

1979 Section 18. **Effective date.**

Effective Date.

This bill takes effect on May 6, 2026.

2-2-26 6:32 PM